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Abstract
Cardiovascular disease is the commonest cause of death in the western world and 
atherosclerosis is the commonest cause of cardiovascular disease. It is characterised by 
the deposition of intra-luminal plaque leading to arterial stenosis. Balloon angioplasty 
offers a minimally invasive method of dilating peripheral and coronary arterial 
stenosis. The results of angioplasty are improved by stenting. However, a significant 
percentage of these patients have restenosis of their arteries with clinical and resource 
implications. Restenosis is caused by neointimal hyperplasia (N1H) and negative 
remodelling the combined effects of which result in vessel re-narrowing. It has 
previously been shown in animal models that photodynamic therapy (PDT) reduces 
the restenosis when used as an adjuvant to angioplasty. PDT involves the interaction of 
light at a particular wavelength with a pre-administered photosensitive agent to 
produce cell death by apoptosis in the presence of oxygen.
The aims of this thesis are two fold. 1. to optimise the effects of PDT in preventing in­
stent restenosis 2. to conduct a randomised controlled trial to show the clinical benefits 
of PDT in preventing post-angioplasty restenosis.
Experimental project
Balloon injury in the rabbit iliac artery was used as a model of NIH and in-stent 
restenosis. 5-aminolaevulinic acid (ALA) was used as the photosensitiser with light at 
635nm for activation. The rabbit iliac artery was stented and adjuvant PDT was given. 
Initial studies established that when light is applied before stent deployment there is
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almost complete depletion of the vascular smooth muscle cell (VSMC) in the media 
with loss of endothelium at 3 days. The vessels were harvested at 28 days. 
Histomorphometric studies showed that in those vessels where light was applied 
before stent deployment there was significant reduction in NIH and in-stent restenosis 
with significantly wider lumens. There was repopulation of the media with complete 
endothelial re-growth. When light was applied after stenting, there was no depletion of 
VSMC at 3 days and no significant inhibition of NIH.
Clinical project
Two clinical projects were run simultaneously. A clinical pilot study had been 
conducted by my predecessor in the department (Mr. Mike Jenkins) showing safety 
and efficacy of clinical use of PDT as an adjuvant to angioplasty. Initial 6 months 
results in 7 patients showed no restenosis. These patients were followed up and at 4 
years showed restenosis at a treated site in only one patient with only mild recurrence 
of symptoms.
A randomised clinical trial was conducted comparing the effect of standard 
angioplasty with angioplasty with adjuvant PDT in preventing restenosis at 6 months. 
All patients with symptomatic stenosis/occlusions in the femoro-popliteal artery 
segment were recruited. While 132 patients were intended to be included in the trial I 
could recruit only 66 patients in 2 years. The trial is ongoing but currently suspended. 
Of the 33 patients recruited in each group, 28 patients in the control group and 25 
patients in the treatment group completed the 6 month follow-up. At 6 months 
although the primary patency rate in the treatment group was better than the control
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group no significant conclusions can be drawn from my results. There were more 
complications recorded in the treatment group but these were easily treated.
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This work is dedicated to my wife.
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Chapter 1. Atherosclerosis
History of arterial disease
Death and taxes, it is said, are the two absolutes of life. As a vascular surgeon however 
one is almost tempted to add atherosclerosis to these. It is inevitable that anyone who 
lives into adulthood will have an atherosclerotic plaque somewhere in their 
vasculature.
Atherosclerosis, derived from the Greek “athero” meaning gruel or paste and 
“sclerosis” meaning hardening, is responsible, directly or indirectly, for the majority of 
deaths occurring in the Western Hemisphere. With life styles changing in the Eastern 
Hemisphere death rates there are also fast approaching western levels.
The ancient Greeks certainly knew of its existence evidenced by the documentation of 
aneurysms in the writings of Galen. However, it is not clear whether they correlated 
this with atherosclerosis. Sophisticated histological analysis has shown the presence of 
atherosclerotic changes in Egyptian mummies. 1
Although clinicians through the 17 and 18th centuries documented atherosclerosis most 
of their attention was directed towards aneurysmal disease. It wasn’t until 1829 that 
the term arteriosclerosis was coined which was later changed to atherosclerosis. 
Rudolf Virchow was possibly the most significant contributor to the understanding of
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the histopathology of atherosclerosis. He published his Handbuch der Speciellen 
Pathlogie imd Therapie in 1854 in which he has further described the role of 
embolism and thrombosis.1
Ignatovski in the early 20th century produced an animal model of atherosclerosis while 
Adolf Windaus won the Nobel Prize for showing the relationship between cholesterol 
and atherosclerosis.
In the 20th century ‘all hell’ it seems has broken loose as our understanding of 
atherosclerosis and its manifestations has increased manifold. With the increasing life­
span of humans characterised by most people, especially in the western hemisphere, 
living well past their 7th decade it has graduated from being merely a medical curiosity 
to the one of the biggest concerns of most health care systems.
Anatomy of an artery
The arterial wall consists of 3 layers the intima, media and the adventitia. It has been 
known for several years now that the plaque formation occurs primarily in the media 
or the interface between the intima and the media. Both of these layers play a 
significant role in the formation of a plaque. Although the intima is only one cell thick 
it’s complexity in function can equal any other cell in the body.
Anatomically speaking the endothelial cell forms an interface between the blood
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components on the inside and the smooth muscle cells and vascular interstitia on the 
outside. It provides a surface of several thousand square metres, which can secrete or 
absorb as required. It is also apparent now that there are differences in the individual 
cell populations depending on the location.
Functionally it is a major player in most if not all homeostatic mechanisms in the 
body. It acts as a selectively permeable barrier with the permeability varying both as 
function of time and location. Given its massive surface it can cause colossal 
imbalances in circulating volume as for example in shock. It thus plays a vital role in 
acid-base balance and electrolytic balance. It acts as a balance for the various pro and 
anti-thrombotic mechanisms by means of regulating the secretion of pro and anti­
thrombotic hormones. Similarly it regulates vasomotor tone by maintaining and 
balancing the secretion of various vasoconstrictor and vasodilator hormones. It also 
plays an important role in the inflammatory and immune responses and repair 
mechanisms by regulating the secretion of cytokines and growth factors.
The arterial media consists of a cellular component, which is primarily vascular 
smooth muscle cell (VSMC), and a complex extra-cellular matrix (ECM). VSMC 
proliferation is a characteristic feature of plaque formation but very little is known 
about the mechanisms involved in this. Although the primary function of the VSMC is 
contraction, it also has a secretory function and is responsible for the secretion of most 
of the ECM. It is believed that in a normal vessel it remains in a differentiated mature 
state with plenty of contractile fibres with very little secretory activity.
The ECM consists of various connective tissue components such as collagen fibres
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types I-IV, elastic fibres such as elastin, glycoprotiens, basement membrane proteins 
such as laminin and proteoglycans such as hyaluronan. Each of these components 
plays varying roles in providing structural strength and elasticity to the vessel. Both the 
composition and the thickness of the ECM varies throughout the vasculature. In areas 
such as the pulmonary and renal vascular beds they are so thin so as to be almost non­
existent while in some vessels such as the aorta they form a significant proportion of 
the vessel wall.
Pathogenesis of atherosclerosis
Since Virchow described the basic structure of atheroma considerable work has gone 
in to the description of plaque origin and structure. Recent opinions about the 
pathogenesis of the atherosclerotic plaque have in fact gone back to the original 
concepts that the plaque was inflammatory in origin. In the 19th century the popularly 
held view was that it was a degenerative disorder. However in the latter part of the 20th 
century our understanding of plaque formation has benefited from extremely 
sophisticated imaging and tissue processing techniques.
In 1994-5 the American heart association committee for vascular lesions proposed a 
classification for the plaques based on its tissue morphology. Plaques can fall in to 6 
categories. Stage I-III included fatty streaks and intermediate lesions while stages IV- 
VI include plaques with varying degrees of added complications.2^
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Early lesions
Fatty streaks are the earliest lesions to be seen in arterial intimas and can be seen even 
in infants. It is almost universally present in the arteries of young adults. These are said 
to originate from the deposition of lipid (probably oxidated LDLs) either in the 
subendothelial plane or between the basement membrane and the endothelium. This 
induces the migration of monocytes, which phagocytose the lipids to form foam cells. 
This forms the basic structure of the fatty streak and is the stage I of plaque formation.
In the presence of continuing insults (such as hyperlipidemia and all the risk factors, 
which will be discussed later) this simple lesion will progress by accumulation of 
smooth muscle cells from the media and the further deposition of lipids. Thus the 
presence of smooth muscle cells pushes it up a stage into stage 11 and extracellular 
deposition of lipids moves it up to stage III. Not all of these lesions necessarily go on 
to stage IV or above and some of them are even known to regress.
Progression to an atherogenous plaque is typically seen in specific sites along the 
vascular tree. These include the:
Circle of Willis
Carotid bifurcation
Coronary arteries
Abdominal aorta
Iliac and lower extremity vessels.
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Late lesions
Stage III lesions are converted into true atherogenous plaques in stage IV. These are 
made up of multiple alternating layers of foam cells and SMC surrounded by 
connective tissue in an uneven complex arrangement. This lesion gets more organised 
with time so as to be raised from the surface of the intima and project into the arterial 
lumen. It acquires a fibrous cap of connective tissue. T-lymphocyte appear in the 
cellular component and the matrix consists of collagen proteoglycans and small elastic 
fibres. This may be interspersed with necrotic debris and may over time get calcified. 
This now falls into stage Va. Most uncomplicated plaques would fall into categories 
IV and Va.
The progression of these plaques into stages Vb, Vc and VI usually leads to some 
acute manifestation of the disease depending on the affected artery. Stage VI is the 
development of acute thrombosis in the plaque. This usually leads to a hyper-acute 
event such as a myocardial infarct or an acutely ischaemic limb. The thrombosis can 
occur because of 2 reasons. The surface of the plaque being very brittle can easily 
rupture leading to exposure of an extremely thrombogenic surface to blood and 
coagulation components. In the presence of an already narrowed lumen with sluggish 
blood flow this is just the right environment for thrombosis to occur. There is also a 
theory that the inflammatory response accompanying an atherogenous plaque 
stimulates the formation of neo-vasogenesis in the outer layers of the vessel. This can 
cause intra-plaque bleeding leading to thrombosis and occlusion.
Alternatively the plaque may undergo a sub-acute change. This usually involves
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some Assuring along the shoulder of the plaque. This leads to bleeding within the 
plaque and may give rise to symptoms though not enough to cause an acute event. 
This over time can get organised in 2 ways. If it acquires a proliferation of VSMC and 
connective tissue then it is classified as a Stage Vb. If however it organises into 
collagen then it is classified as stage Vc.2-4
Risk factors
Risk factor modification has played a key role in reducing the mortality and morbidity 
rates over the last 25 years.
Atherosclerosis is certainly a disease of ageing with prevalence rate showing a sharp 
rise from age 45. Male sex has always been viewed as an important cause of 
atherosclerotic disease. Although this is essentially true in most western countries this 
is less obvious over the age of 75, as women tend to catch up with men. A similar 
pattern is seen in cerebro-vascular disease and peripheral vascular disease but is not as 
marked as in coronary artery disease. Aneurysmal disease however remains a preserve 
of the male with the ratio being 6:1 in the U.K. (The Office of National Statistics 
2000)
Hypercholesterolemia was one of the first risk factors to be directly correlated with 
atherosclerotic disease. 18% of all men and 22.4% of all women in the U.K. had a 
blood cholesterol level of >6.5mmol/l in 1998. Treating hypercholesterolemia has
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been one of the most effective ways of controlling heart disease in the last 3 decades. It 
has been known that LDL-cholesterol is the most important form responsible for 
increasing the rate of atherosclerosis. Recent evidence has shown the oxidised form of 
LDL-cholesterol is probably the most dangerous. HDL-cholesterol has been shown to 
be protective and can sometimes lower the risk of atherosclerosis. Dietary intake of 
polyunsaturated fatty acid as opposed to saturated fatty acids is also supposed to lower 
LDL-cholesterol.56
Smoking has probably been directly or indirectly responsible for most of the deaths in 
the 20th century. Smoking affects cardiovascular disease in multiple ways. To begin 
with the various components of smoke such as nicotine, nitric oxide, cyanides, carbon 
monoxide, polyphenols and multiple other free radicles and antioxidants, each have a 
deletirious effect on the vascular system. Further each component seems to affect 
different homeostatic mechanisms, which contribute to atherosclerotic disease. 
Nicotine and its metabolites have been shown to be cytotoxic to endothelial cells. 
Various components in cigarette smoke are directly responsible for increasing serum 
LDL-cholesterol, triglyceride and VLDL-cholesterol levels while lowering HDL- 
cholesterol levels. These are also responsible for oxidising LDL-cholesterol. This in 
turn has been shown to increase local inflammatory response and cause local 
vasospasm. Several constituents of smoke have been shown to have chemotactic 
properties and also increase leukocyte adherence. It also stimulates the production of a 
number of cytokines along with stimulating components of the complement system. 
Through its metabolites, it also stimulates a sustained immune reaction with increased
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concentrations of all forms of immunoglobulins in the serum. Plasma levels of 
fibrinogen are elevated and this has been shown to directly relate to increased 
cardiovascular events. It is also responsible for increased thrombogenecity by 
inactivating the antithrombotic effects of proteins C and S and tPa, activating factor 
XII stimulating platelet aggregation and increasing the production of thromboxane A2 
and prostacyclin derivatives which preclude the developments of acute events caused 
by plaque thrombosis.7,8
There is no doubt that hypertension is one of the most important risk factors 
responsible for atherosclerosis. Both the Framingham study and the North Karelia 
project showed significant reduction in absolute risks of cardiovascular events after 
effective control of hypertension.910 Moreover blood pressure control is also shown to 
reduce the incidence of asymptomatic peripheral disease. In spite of these observations 
it is not clear exactly how hypertension accelerates atherosclerosis. The virtual absence 
of atherosclerosis in the venous circulation shows that arterial blood pressures are 
needed to promote atherosclerosis. This is further evidenced by the fact that Long 
Saphenous Veins (LSV) used for coronary artery bypass promptly develop 
atherosclerosis. Similarly the pulmonary arteries only develop atherosclerosis in the 
presence of pulmonary hypertension. Hypertension has been shown to increase the 
trapping of LDLs in the intima and the media. What is however not clear, is the 
relationship between hypertension and the predominance of certain sites for 
atherosclerosis. Atherosclerosis is commonly seen at the arterial wall segments 
opposite flow-dividers. For example at the carotid bifurcation the plaques are usually
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seen in the wall opposite the dividing wall. It has been suggested that it is the slow 
flow and the turbulence rather than the high shear forces associated with fast flow, that 
causes the damage required for lipid deposition. Using Bernoulli's principle, since 
there are increased flow rates at the dividing wall and slow flow rates at the opposite 
wall, the pressure differential can be up to 7-8 mm of mercury at normal blood 
pressure with parallel increases as blood pressure rises. This pressure differential could 
be one of the causes of accelerated plaque formation.5,9,10
If atherosclerotic disease is a major cause of death in the general population it is even 
more so in diabetics. More than 80% of all deaths in diabetics are due to 
atherosclerotic disease. Diabetes has been shown to accelerate the natural progression 
of atherosclerosis in all populations. It does so in a number of different ways. It 
increases circulating levels of VLDLs and LDLs as well as changing the compositions 
of atherogenous plaque with increased levels of VLDL remnants and small dense 
LDLs. It also reduces the levels of HDLs. High circulating levels of insulin and insulin 
resistance in non-insulin dependent diabetics (NIDDM) leads to hypertension and 
increased plaque formation. Further hyperinsulinemia causes dyslipidemia impaired 
fibrinolysis, a central pattern of fat distribution and smooth muscle proliferation. 
Diabetes also leads to a pro-coagulant state with increased levels of clotting factors, 
increased platelet aggregability, increased levels of fibrinogen and decreased levels of
11 13plasminogen activator inhibitor type-I.
The role of alcohol remains controversial. Small levels of intake could be beneficial as 
shown in the Edinburgh study, which showed the consumption levels in
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claudicants, were lower than that of the general population. However an intake of over 
2 units a day is generally considered detrimental. Diet certainly plays an important role 
in the treatment of hyperlipidemia and diabetes but it is still open to question as to how 
important a role it plays on its own. Case control studies have shown significantly 
reduced risk with diets high in crude fibre and polyunsaturated fatty acids. Levels of 
exercise and personality types are also shown to contribute to atherosclerotic 
disease.5,6 Increased blood viscosity and plasma fibrinogen levels have consistently 
been shown to be elevated in patients with peripheral arterial disease.
Manifestations
Broadly speaking atherosclerotic disease can be categorised into 4 categories. 
Ischaemic heart disease (IHD)
Cerebro-vascular disease (CVD)
Peripheral vascular disease (PVD)
Others
The manifestations of ischaemic heart disease can range from the relatively benign 
stable angina to a full-blown myocardial infarct leading to sudden death. Angina can 
be either precipitated by stress such as exercise or in its more progressive form be
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present at rest or in the form of unstable angina. IHD can present itself in the form of 
congestive cardiac failure, which may be left or right ventricular, acute or chronic. 
Depending on the vessel(s) involved varying amounts of muscle loss can result from a 
MI. Significant sequelae of a MI include arrhythmia, acute CCF, ventricular 
aneurysms and clot formation, peripheral embolisation and sudden death.
Cerebro-vascular events include transient ischaemic attacks (TIAs), amourosis fugax, 
reversible ischaemic neurological deficits (RINDs) and a full-blown stroke. TIAs can 
be crescendo in nature while a stroke can be in evolution. A stroke may progress to a 
hemiplegia with profound sensory loss and depending on the side can produce aphasia.
Although Peripheral vascular disease can affect both upper and lower limb arteries it 
shows a significant preponderance towards the lower limb vasculature. The symptoms 
are however similar for both upper and lower limbs and present primarily as 
claudication or critical limb ischaemia. Critical limb ischaemic includes rest pain or 
night pain ulceration or gangrene. Leriche syndrome secondary to iliac artery 
obstruction can present as vascular impotence.
Other manifestations of the disease include renal artery stenosis leading to renal failure 
and hypertension and mesenteric ischaemia leading to malabsorption syndromes and 
sometimes infarcted bowel.
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Chapter 2. Peripheral Vascular Disease
Presentations
Although the symptomatology of peripheral vascular disease is fairly simple this does 
not imply that treatment options are equally straightforward. In fact it is not yet clear 
whether interventional or surgical treatment should be offered at all to the majority of 
people with peripheral vascular disease.
It is postulated that the vast majority of people with peripheral vascular lesion are 
asymptomatic. This was first shown in the Basle study which used pulse occilometry 
to measure occlusive disease and showed that the incidence of asymptomatic disease 
was 3 times that of patients with claudication.14 This has been corroborated in a 
number of studies since then including the most recent Edinburgh Artery Study which 
showed 17 % of asymptomatic men had an ABPI of <0.9 or a post-occlusive reactive 
drop in pressure of >20%. This was almost 3 times both the prevalence and incidence 
of claudication in the sample population.15
Claudication
Claudication is considered the early or benign form of the disease. Again it is difficult 
to estimate the number of claudicants in the population for several reasons. Large 
sections of claudicants believe it to be part of growing old and do not even approach 
their doctor for an opinion. Of those who do attend only a small percentage are 
referred on for expert advice. Further it is also dependent on the degree of disability it 
cause the patient which in turn is largely dependent on the lifestyle of that patient. For
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example, 50 yard claudication could mean loss of a job to a 50 year old forest warden 
while the same would hardly affect an 85 year old pensioner. The prevalence of 
claudication has been shown to vary from 0.3% in North American telephone 
employees to 7.7% in all the male population of Finland. The Edinburgh study 
reported the prevalence to be 4.6% overall, while the Southampton study showed the 
prevalence to be 7% in elderly men. The 5-year cumulative incidence in the Edinburgh 
study was 9% while that in the Basle study was 6%.14'16
Both of the above 2 categories of patients i.e claudicants and people with 
asymptomatic PVD are considered benign forms of the disease for good reason. 
Although there is very little data available on the progression of asymptomatic disease 
the Basle study showed progression of asymptomatic disease to claudication in only 
20% and to CLI in only 8% over a 10-year period. Similarly in the Edinburgh study 
only 15 % of patients with major asymptomatic disease and only 7% with minor 
asymptomatic disease progressed to claudication.1415
Follow up studies in claudicants suggest that at least half are improved at 5 years and 
less than a third deteriorate. Only 29% of claudicants in the Edinburgh study still had 
pain at 5 years. Amputation rates, which were low to begin with, have reduced even 
more in the recent years. Bloor in 1961 reported an amputation rate of 7% for 
claudicants of over 5 years and 12% for over 10 years. However 2 studies in the 80s 
have reported a 1-3% amputation rate over 5 years.15,16
This however does not mean that the atherosclerosis does not progress. The Basle 
study showed a prevalence of 25% of CF1D in asymptomatic disease while the
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Edinburgh study found IHD in 54% of asymptomatic patients. Similarly, between 25- 
50% of claudicants had carotid disease on duplex examination. Approximately 30 % 
of claudicants are dead at 5 years, 50% at 10 years and 70% at 15 years the majority of 
them from cardiac events and stroke. 1415
Critical Leg Ischaemia (CLI)
The second category of patients with PVD is those with CLI. The European Working 
Group in Critical Limb Ischaemia defined CLI as persistently recurring rest pain 
requiring regular analgesia for more than 2 weeks or ulceration or gangrene of the foot 
and an ankle pressure of <50 mmHg or absence of foot pulses in diabetics. More 
recently the Audit committee of the Vascular Society of GB & Ireland have redefined 
it as chronic or acute on chronic ischaemia that endangers the whole or part of the 
leg.1718 Rest pain is certainly the pre-dominating presenting feature as is seen in 74% 
of patients with 34% having gangrene and 32% ulceration. Figures published by the 
Audit Group suggest an annual incidence of 50-100/100 000 in Europe and 40/100000 
in the UK.17,18 The figures published in Scandinavia were 60-80/100 000.16 The annual 
prevalence is 1 in 2500 with 20 000 admissions per year in GB & Ireland of whom 
15000 have major surgery.17,18 Wolfe, in the 80s, recorded that 25% of patients 
presenting with CLI would loose their leg in a year.19 The VSS audit however showed 
a one-year mortality of 13.5% and amputation rate of 21.5%. As is the case with 
claudicants, concomitant cardiovascular disease usually kills 50% of patients within 5 
years. Factors that tend to worsen prognosis include diabetes mellitus and continued 
smoking. Other factors which predict early mortality are concomitant symptomatic
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cardiac or cerebro-vascular disease and initial ABPI <0.5.
Critical leg ischaemia can be further categorised as acute and chronic critical 
ischaemia (ACLI and CCLI respectively).
By definition acute limb ischaemia progresses from asymptomatic to limb threatening 
in less than 2 weeks. Pathophysiologically however ACLI can be precipitated by 2 
completely separate phenomena with completely different presentation. Although 
thrombotic occlusion is considered the commonest cause of ACLI embolic arterial 
obstruction is not far behind. The former usually presents as an acute on chronic event. 
There is usually some underlying atherosclerotic disease. The acute exacerbation can 
be precipitated by acute alteration in circulatory dynamics or due to alteration in 
thrombotic properties. The presence of some pre-existing arterial disease even if 
asymptomatic usually means that there is some collateral circulation, which tilts the 
balance in favour of viability of the limb. Embolic events, most commonly from the 
heart in atrial fibrillation or from an aneurysmal abdominal artery (aorta or iliacs), 
however are far more precipitous and need immediate attention if there is to be any 
hope of limb salvage. Although the outcomes both in terms of limb salvage and 
mortality are poor in both categories mortality is greater in embolic events due to poor 
cardiac status while limb salvage is worse in thrombotic events.
Investigations
Typically a patient who presents to a vascular unit with symptoms suggestive of PVD 
will have Doppler examination of his pulses and measurement of his ABPI. Although
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not as sensitive as more sophisticated tests they have good negative predictive value 
and are effective in ruling out significant vascular disease. The measurement of ABPI 
can be made more sensitive by adding an exercise ABPI if the resting ABPI values are 
normal.
Vascular Doppler
Doppler ultrasound in its most basic form relies on the Doppler principle that the 
frequency of sound reflected by a moving object is changed in proportion to the 
velocity of the moving object. This frequency shift falls within the audible range if the 
initial sound frequency is between 5-10MHz. While for a simple outpatient ABPI 
assessment just the presence or absence of the ‘whoosh’ sound is enough, more 
sophisticated equipment can convert this into a spectral waveform which can provide 
more information about the blood flow. For example a normal waveform is tri-phasic 
in nature coinciding with l.A strong forward flow in systole, 2. A transient reversed 
flow and 3. A weak forward flow in diastole. Normal ABPI is >1. Most patients with 
symptomatic PVD will have an ABPI of <0.9. As mentioned earlier an ankle pressure 
of <50 mmHg is suggestive of CLI. It is sometimes possible to have normal ABPI in 
the presence of proximal disease such as aortic or iliac stenosis.
The simple hand held Doppler used in a vascular outpatient clinic has progressed into 
a far more sophisticated instrument capable of providing both structural and functional 
information, so that it is questionable now to use angiography in all cases. 
Contemporary machines are a combination of both Continuous Wave (CW) Doppler 
and B-mode ultrasound giving both an image of the artery and colour coded
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blood flow through it. The Doppler waveform is converted in colour coded waveform 
and superimposed on the ultrasound image of the artery. The reflected frequency can 
also be used to calculate the velocity of blood flow within the artery. Thus a complete 
Doppler ultrasound report would usually include an US image of the artery usually 
with a colour-coded waveform, spectral waveform, peak systolic and diastolic 
velocities. Characteristics of the waveform and the degree of stenosis or occlusion are 
calculated on the basis of the above information. Any stenosis over 50% is considered 
significant and anything over 75% high grade. More sensitive machines can also 
provide information on plaque characteristics such as presence of thrombus and an 
unstable plaque.
The usefulness of a duplex assessment has been proven in a number of studies 
comparing it with the gold standard of arteriography. Various studies have shown a 
sensitivity of 71-98% and specificity of 91-100% when comparing the degree of 
stenosis on US Doppler to arteriography. Newer machines have even been shown to 
be >90% sensitive and specific for infra-crural vessels. In view of its non-invasive 
nature, lack of complications, no contraindications and low cost it forms an ideal first 
investigation in any case of PVD. In selected cases it has been used as the only 
investigation. In carotid disease it is used as the only imaging in most vascular units. It 
is especially useful in those patients in whom angioplasty is possible as it can be 
planned without a preliminary diagnostic angiogram.14,15,20’21
Doppler is also used for Pulse Generated Runoff. This is used to augment a weak or 
absent Doppler signal in distal vessels which may be poorly filling on
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angiograms due to a proximal occlusion. It also helps define continuity with the pedal 
arches thus helping prognosticate distal bypasses.22
Arteriography
Arteriography remains the gold standard in most vascular units for structural definition 
of an arterial lesion. The usual approach is a trans-femoral approach using a 4-5F 
catheter. A standard Seldinger technique is used with guide-wire insertion and guiding 
the catheter over the guide wire. A pigtail catheter is inserted in to the distal aortic 
segment and a non-ionic contrast (usually iodine based) is injected. Most procedures 
are done under image intensification and hard copies are shot at appropriate times. 
Most units are now computer aided which give digital images. This makes it possible 
to have multiple views and also to digitally subtract bone and soft tissue artefacts thus 
providing most if not all the information required in planning treatment. The small 
calibre of the catheters leaves an extremely small defect in the arterial wall, which 
usually plugs off with simple pressure. Vaso-seal devices are now available if there is 
a need for larger catheters. Alternative sites of puncture include the radial and brachial 
artery in the upper arm or the poplitial or the external iliac artery just above the 
inguinal ligament. It is also possible to inject dye through a peripheral vein and create 
a digital subtraction angiogram. An added benefit is the ability to directly measure the 
pressure gradient across lesions, which is useful in deciding the need for an 
angioplasty.
While angiograms are a very useful tool in grading PVD the procedure cannot be
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carried out in all patients and it has a small incidence of significant complications and 
even death. Although death rates have gone down considerably a large audit of 
complication following angiograms in the ‘80s showed a death rate of 0.03% 
following trans-femoral angiography for non-cardiac pathology. More recent studies 
such as the one by Egglin et al showed no mortality for non-cardiac and non-cerebral 
procedures. However major complications occurred in 2.9% cases and minor 
complications in 9.3% of cases. Specifically for PVD there was a 2% major 
complication rate and a 7% minor complication rate.23 Major complications include 
arterial dissection, femoral artery thrombosis, pseudo-aneurysm formation and 
bleeding, distal embolisation and renal failure. There is almost invariably some 
bruising at the site of puncture and quite often sustained pressure is needed to stop on­
site bleeding. Vaso-vagal attacks are common. They however can be especially 
dangerous given the poor cardio-respiratory reserve of a lot of the arteriopath patients. 
The contrast used can give rise to hypersensitivity reaction nephrotoxicity and in larger 
volumes can precipitate CCF. Patients have to lie still and flat for anything ranging 
from 20 minutes to an hour. Hence orthopnea is a relative contraindication as is renal 
failure and any bleeding diathesis including patients who are on warfarin. Metformin, 
an oral hypoglycaemic agent, has to be stopped for 48 before as recommended by the 
Royal College of Radiologists and restarted only after checking renal function after the 
procedure as it can precipitate lactic acidosis and renal failure.
Others
Because of the problems associated with invasive arteriography a number of non-
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invasive imaging techniques have been tried and some of them are proving to be very 
useful and may in the future replace conventional angiography. Spiral and 3-D 
reconstructive CT scan has revolutionised the imaging in proximal PVD providing 
excellent images of the aorto-iliac segment. The obvious disadvantages are the amount 
of radiation involved and the cost. Magnetic resonance angiography has also recently 
come into vogue and shows good promise. Gadolinium has been used as a contrast 
medium and certainly provides very good pictures. Specific arterial segments can be 
very well visualised and it may be useful in delineating run-off vessels if angiography 
does not give good images. Again the problems are those of cost and patient 
compliance with the machine.
Older techniques, no longer commonly used, include plethysmography which measure 
short-term changes in limb volume. Blood flow measurement using isotope scanning 
are no longer used routinely and are reserved only for laboratory use. Similarly trans- 
cutaneous oximetry has been used to assess tissue oxygenation.
Techniques that may have an application in the future include intravascular ultrasound 
and angioscopy. With fibre-optics getting better and finer there are now angioscopes 
available for clinical use. They have as yet failed to gain popularity although some 
units have used them intraoperatively to check anastomotic sites. Intra-vascular 
ultrasound (IVUS) can prove to be quite exciting, as the quality of images is better 
than those provided by any other imaging. Cross-sectional images provided by an 
IVUS can be converted in to a longitudinal image of amazing accuracy and are 
especially useful in checking lumens after angioplasty or stenting.
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The quality of images available today is truly remarkable and certainly there is great 
promise in the newer techniques available. They can however only supplement a good 
history and clinical examination. As a very wise physician once said “treat the patient 
not the investigation”.
Treatment options
Broadly speaking treatment of PVD can be divided into medical management and 
interventional options.
Medical Management
As discussed earlier there are a number of risk factors implicated in the causation of 
PVD. It follows that risk factor modification could play an important role in the 
treatment of PVD. However most of the evidence that exists in the value of risk factor 
modification is circumstantial and derived from studies for cardiovascular or cerebro­
vascular disease.
Stopping smoking is one of the most important recommendations to all patients. 
Physiologically this will help in multiple ways. Acutely it reduces vasospasm, 
increases blood and tissue oxygen levels, and lowers blood nicotine and homocystene 
levels. In the medium and long term it slows and possibly reverses atherosclerosis 
restores normal thrombogenecity of the blood, improves RBC pliability and opens up 
capillary bed and collateral circulation thus improving tissue perfusion. By its effects 
on coronary circulation it also improves cardiac function thus improving output.24
Treatment of hyperlipidemia using statin drugs has been shown to reduce
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cardiovascular events in a number of large studies. The risk reduction of 
cardiovascular events follows an almost parallel course with risk reduction of 30% 
with a reduction in cholesterol level by 25%. It has been shown to be of most benefit 
in secondary prevention but also has some benefit in primary prevention. However 
such strong evidence does not exist for PVD. However since a large proportion of 
patients of PVD have cardiac disease as well, there is certainly no harm in lowering 
cholesterol levels using statins.25,26
Control of blood pressure and diabetes mellitus plays as important a role as control of 
cholesterol levels in the treatment of PVD. Doubts have been expressed as to the 
adverse effect that lowering blood pressure would have on tissue perfusion. However 
this is probably of little significance compared to the systemic benefits of good blood 
pressure control. Control of diabetes is important in more ways than one. Controlling 
diabetes has been shown to reduce the risk of microangiopathy which contributes 
significantly to the morbidity of large vessel disease. Similarly because of the added 
aspect of peripheral neuropathy minor injuries can precipitate the development of CLI 
early. Good control also reduces infection rates and thus helps in early healing of 
vascular ulcers.27
Getting out of a sedentary lifestyle is probably as difficult as stopping smoking but a 
graded exercise programme is one of the few life-style modifications that has been 
shown to make a significant difference to claudication distance even as compared to 
angioplasty. In a well-designed study Perkins et al from Oxford compared a graded 
exercise programme with angioplasty.28 While the improvement following
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angioplasty was better at 3 months, at assessments at 6,12 and 15 months those on the 
walking programme did significantly better. Another study in Edinburgh showed 
similar results. The early results (6 months) were much better with angioplasty, but at 
2 years of follow-up both showed an equal walking distance which was much better 
than their presenting walking distance.29 A meta-analysis of 21 studies showed that 
there was mean improvement in walking distance of 105% (SD 56%). Factors which 
improved results include exercise for at least 30 minutes, 3 sessions or more a week 
and walking to the limit of pain as the main form of exercise. 30 31A note of caution 
was produced by the Oxford study which showed that after 70 months of follow up, 
although only 1/3rd of the patients were available for follow up, their walking distance 
had deteriorated, although it was still better than their presenting claudication distance.
The data for the use of anti-platelet agents is similar to that for cholesterol lowering 
drugs and control of hypertension. The Anti-platelets Trialists' Collaboration showed 
that aspirin lowered the rate of MI and stroke by 25%. Similarly the CAPRIE study 
has shown that that both Clopidogrel and Aspirin significantly lowered the risk of 
cardiovascular events. Subgroup analysis showed that the relative risk of PVD was 
reduced by 24%. Ticlopidine is another anti-platelet agent, which has been tried and
32*33showed to have beneficial effects. ’
Prostanoids are probably the most investigated drug in the treatment of CLI. 
Prostanoids such as Prostacyclin (PCI2) and Prostaglandin Ei act at the 
microcirculatory level due to their anti-platelet, anti-leukocyte, vasodilatory and 
cytoprotective effects. The stable analogue of PCI2 Ileoprost is used as an
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intravascular infusion in the dose of up to 2mg/kg/minute for upto 2-4 weeks. At 
present its use is restricted to those patients in whom reconstructive surgery is 
unsuitable but who nevertheless have rest pain or ulcers. They have also been tried 
before amputations and have been shown to give better healing rates. A meta-analysis 
of six controlled studies of ileoprost suggested an advantage in terms of reducing 
mortality and amputation rates.34
Adjunctive therapies that have been tried include HRT in post menopausal women, 
anti-oxidants, drugs lowering plasma homocysteine levels such as folates.
Gene therapy has been used experimentally to stimulate angiogenesis and certainly 
shows promise. All the medical therapies are summarised in Table 2.110,26>27’32'36
Surgery and interventional radiology
The advent of angioplasty in the 1980s radically changed the treatment options adding 
a very powerful weapon in the battle to preserve legs. Certainly a large chunk of a 
vascular surgeons PVD workload has been taken over by the interventional 
radiologist. Given the topic of this thesis, angioplasty deserves a detailed discussion 
and will be dealt with in greater detail in the next chapter.
Having said that, surgery still plays an important role in the treatment of PVD 
primarily because it provides the best long-term results. The principles of vascular 
surgery are fairly simple. For surgery to work there has to be a good inflow, a good 
outflow and good conduit with sound anastomosis. Surgery can be divided into 
anatomical and extra-anatomical. It can further be divided into supra and infra 
inguinal. Supra-inguinal bypasses include aorto-bifemoral, ileo-femoral,
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Generic therapy Drugs Clinical benefit Evidence/Reference
Anti-platelet
Agents Aspirin, Clopidogril, Ticlopidine
Risk factor modification, 
Improved micro-circulation CAPRIE, Anti-platelet Trialists
Prostanoids Prostacyclin, ProstaglandinEj Vasodilation, Anti-platelet, Cytoprotective U.K severe limb ischaemia study group
Anti-cholesterol Statins Risk factor modification Scandinavian study
Anti-hypertensives ACE inhibitors, Ca-channel blockers Risk factor modification Framingham study
Anti-diabetic Insulin Risk factor modification, improved microcirculation, reduced infection U.K prospective diabetic study
Lowered
Homocysteine Vitamins B\2 B6 and folate
I of NO inhibition of VSMC 
proliferation Shearman et al
Oestrogen HRT cardioprotective Hulley at al
Anti-oxidants Vitamin C & E P carotene Inhibition of atheroscelrosis Shearman at al
Gene-therapy VEGF VSMC inhibition Manninen et al
Table 2.1 Medical management of peripheral vascular disease
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femoro-femoral and axillo-uni or bi-femoral grafts. Results for supra-inguinal grafts 
tend on the whole to be very good with long term patency of >90% at 5 years being 
quite common. However, if it involves aortic or iliac explorations the morbidity and 
mortality is substantially higher.
Infra-inguinal operations include endarterectomies usually at the bifurcation of the 
common femoral artery (CFA) and bypasses from the CFA to either the above or 
below knee popliteal artery (AK or BK), the calf vessels or the pedal vessels. Bypasses 
are also performed from the popliteal artery to the calf or pedal vessels. As is to be 
expected, results get worse the lower down the leg the anastomosis is.
The commonly used conduits are autologous vein or synthetic grafts. Veins can be 
harvested from ipsilateral or contralateral long or short saphenous veins (LSV or 
SSV), deep veins of the leg, or the superficial arm veins. Ipsilateral LSV is the most 
commonly used graft and can be used either in-situ by destroying the valves using a 
valvulotome or by dissecting out and reversing the vein. The 2 commonly used 
synthetic conduits include Polytetraflouroethelene (PTFE) and Dacron. On the whole 
for supra-inguinal bypasses there is no proven advantage in using vein over synthetic 
graft except in infected fields. In the infra-inguinal bypasses veins are by far better. 
The medium term results for femoro-AK popliteal bypasses using vein and synthetic 
grafts are the same (70-80% at 1 year). However, long term results are much better 
using vein, with synthetic grafts starting to fail at about 3-4 years. In bypasses to below 
the knee veins are superior by far and should be used as far as possible. The patency of 
synthetic grafts has been shown to be better if a vein cuff such as a Miller’s cuff or a St 
Mary’s boot, is used at the lower anastomosis. The reasons for graft failure
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include poor anastomosis or preparation of the graft, infection, neo-intimal hyperplasia
(NIH) and disease progression.37
Outcomes
As clinicians we see only the tip of the iceberg as far as PVD is concerned. As 
mentioned earlier a vast majority of patients are asymptomatic. Even among those 
who are symptomatic only a proportion present to their doctor (Oxford study-50%, 
London-<10%).16 The estimated annual workload for CLI alone in GB & I estimated 
by the VSS Audit, is 21450 legs in 20000 patients leading to 12810 revascularisation 
procedures and 4860 amputations.18 The overall success rate for all revascularisation 
procedure is only about 75%. However for both claudication and for CLI there is no 
doubt that the quality of life improvement after successful intervention is remarkable. 
While surgery does produce a more sustained response there is always an associated 
mortality and morbidity. It may seem like an excessive risk, especially for claudicants. 
Angioplasty and its adjuvant treatments hence have the potential to play an important 
role in filling this need for a low risk procedure. Its biggest drawback is its utility being 
limited to proximal disease. This is where a lot of effort is being concentrated, as we 
shall discuss in the next chapter.
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Chapter 3. Angioplasty
History
As with so many useful breakthroughs, angioplasty was first performed quite 
serendipitously by Charles Dotter in the USA in 1963.38;39 While performing an 
aortogram he pushed a catheter through an occluded iliac artery in a retrograde manner 
thus opening up a channel to the aorta. A year later he carried out the first deliberate 
procedure in a woman with gangrene who was refusing amputation. He used a co­
axial system of catheters. A guide-wire was introduced and an 8F Teflon catheter was 
guided over it. Further dilatation was achieved by passing a 12F catheter over the 
indwelling catheter. As can be imagined this left a rather large hole in the artery. There 
was a lot of enthusiasm for the technique in Europe but not so in the US except for 
Dotter and his group. Although Dotter is also credited with using a balloon catheter for 
dilatation his balloon was too thrombogenic and the technique was given up quickly. 
Porstman first introduced a balloon with a Teflon cage, which gave it added strength.40 
However its uneven outer surface it was still too traumatic to the vessel wall. Gruntzig 
first developed a double lumen polyvinyl chloride balloon, which could be inflated to 
up to 5 atmospheres.41 The forces acting on the plaque were more radial than axial thus 
leaving a smoother contour and a better result. The balloon system was further 
improved by the introduction of the polyethylene balloon. Concurrently guide-wire 
materials have also improved with most peripheral guide-wires 0.035 to 0.038 inch in 
diameter. They can be soft tipped with high torque, which allows atraumatic passage
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through occluded and tortuous arteries.
Procedure
Percutaneous transluminal angioplasty (PTA) is ideally carried out in a specialised unit 
specifically equipped for interventional vascular procedures. The concept of an 
endovascular operating theatre is quite popular in the US but although suggested has 
not quite caught on here in the UK. This primarily involves a sterile operating room 
with a ceiling mounted C-arm X-ray unit with a radiolucent operating table made of 
carbon fibre. The most commonly used imaging system is a high-resolution 
fluoroscopy unit with road-mapping capability.
The technique used universally is the Seldinger technique.42 In case the femoral pulse 
is not felt a smart needle may be introduced under ultrasound guidance. After puncture 
of the common femoral artery (CFA) a short guide-wire is introduced through the 
needle antegradely for the SFA and retrogradely for the CIA. An introducer sheath is 
then railroaded over the guide-wire and its position is usually confirmed with a small 
injection of contrast. After systemic heparinisation a longer guide-wire is introduced 
through the sheath and the stenosis or occluded segment is passed. Special guide-wires 
may be needed to traverse difficult occlusions in tortuous vessels especially distally. 
Once the guide-wire is passed beyond the lesion pressure measurements can be taken 
to record the gradient across the lesion. The appropriate balloon catheter is then guided 
over the guide-wire. The radioopaque markers marking the ends of the balloons are 
used to advance the balloon and position it along the lesion. The balloon is then 
inflated using dilute contrast. It is usually inflated to a pressure of 6-10 atmospheres
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and is usually held inflated for about 60-90 seconds. After deflation of the balloon the 
catheter is withdrawn and a completion angiogram is done. If the angiographic result is 
not good enough, the inflation can be repeated one more time. The pressure can be 
increased in order to fracture the plaque. The result can be measured in two ways. The 
residual narrowing should be <30%. Alternatively the pressure gradient across the 
lesion should be abolished or <10 mm Hg. In the presence of vasospasm vasodilators 
such as papaverine or nitro-glycerine can be flushed down the catheter into the arteiy. 
Once satisfied with the result the catheter and guide-wire is gently pulled out. It is 
important to confirm meticulous haemostasis at the puncture site especially if the 
patient is anticoagulated. Most oozing stops by simple pressure. A device known as a 
Vaso-seal can been used if required, to plug the arterial puncture site with good effect.
The mechanism by which angioplasty causes dilatation of the artery, has been well 
studied. Dotter had initially suggested that it was purely because of compression of the 
plaque and draining out of all the water and the lipids from the plaque.38 This has 
however been shown to be negligible following angioplasty. Animal experiments 
have shown there to be stretching of the intima media and adventitia. There appears to 
be straightening of the elastic fibres in the media and a corkscrew deformity of the 
nuclei of the VSMC. Dilatation of post-mortem atherosclerotic arteries has been 
shown to cause plaque fracturing and cracking and dehiscence of the intima and 
media. This may lead to dissection in the media. The disrupted arterial layers heal by 
formation of neo-intima and scar tissue. There is even a suggestion that the more the 
calcification, the better the fractures, contributing to a better eventual result43^ 6
However a recent study which looked at intravascular US of the lesion before and after 
angioplasty has shown that the higher the echogenicity of the plaque the worse the 
outcome because of both acute thrombosis and restenosis.47 This in physical terms 
means that the higher the quantity of fibrous tissue and calcification the worse the 
results. It even suggests that angioplasty should be reserved for plaques with low 
echogenicity. Work still remains to be done to understand the mechanisms involved in 
angioplasty, which might have a bearing in preventing restenosis.
Outcomes
When Dotter et al first reported their cases in 1965, there was initial apathy to testing 
this new technique, especially in the US. However since the late 1970s there has been 
a plethora of publications testing the use of angioplasty. Most papers in the 1980s 
showed a high rate of long term success. However these rates have shown a downward 
trend in the 1990s. There are a number of possible reasons.. The most likely reason is 
that angioplasty is attempted for increasingly difficult lesions and more distal lesions. 
Secondly, the criteria used for assessing patency has shifted from just clinical 
assessment and measurement of ABPI to duplex scanning of the angioplasty sites. The 
Standards of Practice Committee of the Society of Cardiovascular and Interventional 
Radiology with Robert Rutherford laid down guidelines in 1991 for reporting results in 
PVD.48 50 The recommendations were.
1. Patency has to be defined as a.) Primary patency as a period of
uninterrupted patency without further intervention b.) Secondary patency as the 
outcome following one or more re- interventions to restore blood flow in a
50
non-functioning PTA or graft, and c.) Assisted primary patency whereby patency in a 
failing graft or PTA was diagnosed and early remedial action taken before the graft or 
PTA failed completely.
2. Patients in a series should include the whole cohort treated within the 
time-span of the study in an intention to treat manner, without exclusion of initial 
technical failures and death from final results.
3. Patients should be graded according to their presenting symptoms:
Grade I Claudication mild to severe 
Grade II Ischaemic rest pain 
Grade III Tissue loss
4. Outcome measures should confirm to objective assessments of patency 
including one or more of the following: angiography, duplex and maintenance of 
improvement in segmental pressure index.
Iliac angioplasty
Angioplasty is definitely the treatment of choice for iliac lesions and should be 
attempted before any surgical procedure is considered. Most recent series have 
reported an initial success rate of over 90% and 2-year patency of over 80%. Any 
surgery in this area has a very high morbidity and a peri-operative mortality of at least 
5%. Surgery is nowadays considered only when angioplasty fails and some form of 
intervention is absolutely indicated. Table 3.1 lists the results of iliac angioplasty.51*55
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Author Year Indication No of patients/PTA Assessment Vessel
Patency
iy 3-5y >5y
Johnston 1993 claudication 313 Clinical CIA&EIA 81 68 52
Spence 1999 CLI 68 Duplex CIA& EIA 85
Hassan Khodja 1998 Claudication/CLI 163 Clinical CIA&EIA 84 63
Powell 2000 Claudication/CLI 87/207 Duplex CIA&EIA 61 43
Timaran 2001 Claudication/C LI 247 Duplex
CIA 92 85 76
EIA 76 56 56
Table 3.1 Major series reporting outcome of iliac angioplasty.
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Femoropopliteal angioplasty
Results for angioplasty to femoro-popliteal segments of the lower limb vasculature 
have not been quite so successful. Matsi et al who were one of the few investigators to 
use Duplex to assess the patency of the angioplastied site, reported a 1 year patency of 
only 47% and a 2 year patency of 42%. Other studies using either clinical assessment 
or ABPI measurement have reported 1-year patencies from 58-65% and 2-year 
patencies of 45-53%. There have been only few studies that have followed up patients 
for longer than 2 years. Johnstone et al reported a 5-year patency of only 38%. The 
results for femoro-popliteal angioplasty are summarised in table 3.2.56-61
It is immediately clear than results of angioplasty in the fern-pop segment are much 
worse compared to the iliac. Similarly results in the periphery tend to be worse than 
coronary vessels. While there is no strong evidence to explain this, it is believed to be 
due to differences in the lesions and the flow patterns in the 2 circulations. The lesions 
in the coronary vessels tend to be focal and short lesions while in the periphery they 
are much longer. Hence longer segments need to be angioplastied which in turn 
adversely affects the results. The procedure causes more injury and leaves a larger area 
without endothelial cover. There also tens to be concurrent lesions along other 
segments of the vessel in the periphery which influence the flow in the vessel. The 
velocity of flow within the coronary artery is also much higher, again leading to better 
results and patency.
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Author Year Indication No Of Patients/PTA Assessment Technical Success
Patency
iy 3y 5y >7y
Johnston 1992 Claudication/CLI 236/254 Clinical 96 63 50 38
Matsi 1994 Claudication 106/208 Clinical 88 47 43
Gray 1997 Claudication/CLI 55/131 Duplex 100 22
Golledge 1999 Claudication/CLI 74/74 Duplex 91 51
Karch 2000 Claudication/CLI 85/112 Duplex 96 69 49
Bucek 2002 Claudication/CLI 166/166 Clinical 88 44 33
Table 3.2 Major series reporting outcome of femoro-popliteal angioplasty
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Complications
Lower limb angioplasty is a relatively safe procedure with a very low rate of 
complications. Moreover the majority of the complications are easily managed. The 
complications following angioplasty can be divided in to puncture site complications, 
angioplasty site complications and systemic complications.
The commonest puncture site complication is bleeding and haematoma formation. 
Gardiner et al reported a rate of 4% in 352 patients, of which only one needed surgical 
intervention.62 There was only one false aneurysm. These are caused by persistent 
oozing from the puncture site and formation of an organised haematoma around the 
vessel. Although these were fairly common in the early series they are rare nowadays. 
Ihey can be treated non-surgically with thrombin injections into the pseudo­
aneurysms or with pressure at the arterial puncture under duplex guidance. Other 
complications include infection of the puncture site and thrombosis.
The most common angioplasty site complication is thrombosis and acute occlusion. 
These tend to occur at more distal sites of angioplasty such as the popliteal and the 
tibial vessels. Thrombolysis is usually sufficient to reverse this. However surgery 
should be considered if there is no prompt response to the thrombolysis. Similarly one 
can trigger distal embolisation. However these tend to be minor with no clinical 
consequences. Matsi et al reported 11 cases in 410 angioplasties most of which did not 
need any treatment.63 Dissection and sub-intimal passage of the guide-wire and 
catheter is another possible complication. However as we will discuss later sub-intimal 
angioplasty which involves deliberate dissection into the sub-intimal plane is now a
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treatment option.
Systemic complications include fluid overload due to the injection of dye leading to 
CCF especially in patients with pre-existing cardiac problems. Renal failure can be 
precipitated by the iodine in the contrast media especially in diabetics. It is 
recommended that Metformin an oral anti-diabetic agent is stopped for 48 hours 
before angioplasty as it increases the chances of precipitating renal failure.
In a review by Eikelboom et al of 9627 peripheral PTAs the overall complication rate 
was 11.8%with 4.1% being major complications. Only 2.6% needed surgery. The 
overall mortality was only 0.28% similar to Gardiner's series with a mortality of 
0.3% 62;64
Adjuvant treatments
The problems of both early failure and later restenosis following angioplasty have 
prompted a number of adjuvant and alternative therapies to be tried with varying 
success.
Stenting
When Dotter first described angioplasty he hypothesised that in some cases a frame 
may be needed to keep the angioplastied site open. He went on to invent a coil stent 
made of nitinol, which is an alloy of nickel and titanium. This material has a most 
useful property of expansion on exposure to body temperature and can be compressed 
by cooling in order to fit around a catheter.
The stents work on the basic principle of providing a frame, which prevents the
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recoil and collapse of the angioplastied vessel. This would invariably lead to 
thrombosis of the vessel and immediate occlusion. There are currently 2 types of stents 
in use. The Palmaz stent (Cordis Corporation, Warren NJ) and the Strecker stent 
(Medi-Tech, Watertown MA) are balloon-expanded stents. These either come pre­
mounted on an unexpanded balloon or have to be mounted on it and crimped to fit 
around the balloon. When the balloon expands the stent opens up and fits snugly to the 
wall of the vessel. The second type of stent used is the self-expanding stent such as the 
Wall stent (Schneider (USA), Inc., and Minneapolis MN) and the Gianturco Z-stent 
(Cook, Inc., Bloomington IN). These come mounted on a separate catheter and have a 
sheath covering it. Once inserted and in place the sheath is withdrawn and the stent 
opens up and positions itself. These stents are not covered and hence leave the side 
branches open so that the collateral circulation is not compromised These stents are 
available in varying diameters and lengths. Stents are used commonly in CIA disease 
with good success. A number of studies have shown a 2-year patency of about 80%. In 
one series by Vorwerk et al the 2-year patency for occlusions was 83%. Although 
there was a good deal of enthusiasm for the use of stents for iliac disease this is waning 
because studies by Richter and the Dutch Iliac Stent Trial Study Group showed no 
benefit in primary stenting65,66 It is now used only in selected cases. Table 3.3 
summarises the recent results with iliac stening.65-74
Stents have been used inffa-inguinally as well with varying success rates. In one series 
by Gray et al the one-year patency was only 22% of 58 patients. However these were 
long occlusions with poor run-offs in the majority of cases. In general results for inffa-
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inguinal stenting are poor. Table 3.4 summarises the results from some recent trails.75' 
79 The explanation given for the poorer patency in femoro-popliteal arteries as 
compared to the iliac is the smaller calibre of the vessel. The coronary vessels are 
however not much bigger than the femoro-popliteal vessels, but the results in the 
coronary are significantly better. As discussed earlier this is mainly because of the 
lesion size and flow characteristics. Short focal lesions with fast flow in the in the 
coronary, means that the stents are short and disruption of the intima is reduced. Long 
lesions in the SFA with presence of disease in other segments of the vessel necessitate 
the need for longer stents which don’t work.74 Coupled with slower blood flow and 
increased intimal injury this leads to platelet aggregation and fibrin deposition and 
greater restenosis. All of these patients are on aspirin unless otherwise contraindicated. 
However the results of stents have been further improved with concurrent use of 
clopidogrel and Ilb/IIIa antibody such as Reopro. Similarly with the advent of drug- 
eluting stents there has been a dramatic improvement in the results of coronary 
stenting. This has not yet been duplicated in the periphery. In the periphery all patients 
are on aspirin but there is no evidence that clopidogrel or Reopro improves results. 
Sub-intimal angioplasty
80This is a recent technique described first by Bolia and associates from Leicester. The 
technique, done via an ante-grade approach through the ipsilateral CFA, involves 
creating a deliberate dissection between the intima and the media using a floppy tipped 
guide-wire. Sometimes a pre-shaped catheter called a Cobra may be needed. Entry into 
the sub-intimal space is confirmed by injection of contrast.
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Author Year Indication No Of Patients /Stenting Assessment Technical Success
Patency
iy 2y 5y
Sullivan 1997 Claudication/CLI 288/424 ABPI/angio 88 81 73
Raza 1998 Claudication 22/22 Duplex 95 95
Toogood 1998 Claudication/CLI 50/50 Duplex 80 65
Whatling 2000 Claudication/CLI 51/51 Duplex 78 52
Saha 2001 Claudication/CLI 50/61 Duplex 97 94
Timaran 2001 Claudication/CLI 103/103
Clinical EIA 76 56 56
Clinical CIA 92 85 76
Timaran 2003 Claudication/CLI 136/136 Clinical 85 72 64
Tetteroo 1998 Claudication
Stent to all -  143/143 Duplex 81 71
PTA+Selective stenting - 
136/59 Duplex 82 70
Table 3.3 Major series reporting outcome of iliac stenting
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Author Year Indication No Of Patients /Stenting Assessment Technical Success
Patency
iy 2y 3y
Stecker 1997 Claudication/CLI 80/80 Clinical 51 48
Gray 1997 Claudication 55/55 Clinical 46
Cejna 1998 Claudication/C LI 33/33 Angiogram 97 60 73
Cheng 2001 Claudication 60/105 Duplex 93 63 54
Pozzi 2003 Claudication 23/51 Duplex 91 67 46
Table 3.4 Major series reporting outcome of femoro-popliteal stenting
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This usually being the plane of least resistance through the occlusion, the guide-wire 
usually passes through the occlusion easily. The straight wire is replaced by a J-shaped 
wire, which is used to re-enter the lumen 2-3 cm. distal to the occlusion. A balloon 
catheter is passed over the guide-wire and used to perform the angioplasty by inflating 
it to about 10-12 atmospheres of inflation for about 15 seconds. Bolia et al reported on 
200 patients (154 in the femoral and 46 in the popliteal). Primary success was 80%. 
The 1-year patency was 56%, which was however based only on clinical findings.81’82. 
While results in other centres have not been as good as in Bolia’s group nevertheless 
they have reported some success. It is especially useful in critically ischaemic limbs 
where the only alternative is amputations.83’84 Bolia’s group have recently published 
results at 36 months with limb salvage rates of 94% with clinical improvement in 
84%. It certainly plays an important part in limb salvage procedures if the only
O C  0* 7
alternative is surgery and has been tried even in infra-popliteal vessels.
Others
Atherectomy is the removal of plaques by cutting, pulverising or shaving them off the 
arterial wall. A number of devices have been used, which usually consist of two parts, 
one to actually destroy the plaque and one to collect the debris so that it doesn't 
embolise distally. The AtheroCath (Devices for Vascular Intervention, Redwood City 
CA) consisted of a rotary cutting device and a distal collection chamber. The TEC 
system (Interventional Technologies, San Diego, CA) also used a rotary cutting device 
but used suction to clear the debris. The Auth Rotabulator (Heart Technologies, 
Bellevue, WA) consists of a burr rotation at 1,00,000 rpm which causes fine particle
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abrasion of the plaque.
However none of these devices have yet proven their efficacy and are not used 
routinely in clinical practice.
In the early 90’s there was a lot of enthusiasm to use lasers to bum a hole through an 
occlusive plaque. Nd-YAG and argon lasers have been used to create a hot tip at the 
end of the laser probe. This vaporises the plaque tissue. The passage created was then 
used for angioplasty of the occlusion. However enthusiasm has since diminished due 
to an unacceptably high complication rate and poor initial and late results.
Some newer methods which are still in the experimental stage include an intravascular 
ultrasound device which pulverises the plaque using ultrasonic waves and a 
modification of the stents to use stent grafts made of PTFE. These stent grafts however 
have to be put in by an open arteriotomy and can either be left intravascularly or be 
continued down as a femoropopliteal or distal bypass.
Summary
Angioplasty is the first line treatment for iliac arterial obstructive disease. Although 
not as efficacious in infra-inguinal disease it is still considered first line treatment if 
interventional treatment is needed. It has reduced the need for surgical intervention in 
the vast majority of cases and revolutionised the approaches to PVD. But with every 
new modality arises a new set of problems. Restenosis remains the biggest challenge 
for vascular biologists and will be investigated in further detail in the next chapter.
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Chapter 4. Restenosis
Restenosis is a mechanical obstruction to blood flow that occurs after an initially 
successful vascular intervention. It can occur after angioplasty, stenting and surgical 
revascularisation such as a bypass or endarterectomy. Its incidence depends on the 
method of detection and criteria for assessment. While in coronary disease assessment 
is based on angiographic findings in peripheral disease it is often clinical. Doppler and 
Duplex assessment provide an excellent non-interventional alternative to angiography.
The quoted incidence of restenosis is only relevant when the method of assessment 
and definition of restenosis are stated. Even though it is an ongoing process for clinical 
comparison the assessments have to take place at specified time points in order to 
facilitate clinical comparison. The assessment and definition of restenosis will be 
considered next.
Diagnosis of restenosis 
Clinical assessment and ABPI
Traditionally all patients who have had a peripheral vascular intervention are assessed 
clinically and by Ankle Brachial Pressure Index (ABPI) measurement. Clinical 
evaluation involves recurrence of symptoms and walking distance. In patients with 
CLI this is easy. Persistence or recurrence of rest pain, non-healing or recurrence of 
ischaemic ulcers and new areas of non-viability are easily documented. Early 
manifestations of return in rest pain includes rest pain on elevation presenting as night 
pains. Assessment of claudication is more subjective with change in walking distance
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on the flat being a good indicator of outcome. This can however be obscured by 
co-existing conditions such as arthritis and spinal stenosis. Similarly presence of 
exercise intolerance and dyspnoea may further influence walking distance. Walking 
distance can be objectively assessed by a treadmill test. Presence or absence of 
peripheral pulses is also a subjective assessment as the ability of various clinicians to 
palpate pulses varies and it only differentiates between patent and occluded vessels.
Measurement of ABPI is a more objective assessment of deterioration in peripheral 
circulation. This is ideally measured using a hand-held Doppler probe. Any recurrence 
of symptoms or worsening of ABPI is indicative of a problem and certainly needs 
investigation. A fall in ABPI of >0.15 is considered significant.49 The sensitivity can 
be increased by measuring pre and post exercise values. The biggest drawback is that 
it is not lesion specific and is unable to differentiate between restenosis at the 
intervention site and a new lesion.
Duplex surveillance
Duplex is an excellent initial investigation in the assessment of restenosis. It has the 
ability to not only visualise the lesion but also to quantify it. Duplex is the combination 
of a B-mode ultrasound and a pulsed wave Doppler. The Doppler signal can be 
converted into a flow image superimposed on the ultrasound image with colour or 
gray-scale coding to indicate direction and velocity of flow. Thus it demonstrates a 
restenosis by showing narrowing of the lumen in both the transverse and longitudinal 
plane and quantifies the narrowing by the alteration in the velocity of flow. This is 
usually expressed as a ratio of velocity at the area of restenosis and the velocity of
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flow at the closest normal lumen also known as peak systolic velocity ratio (PSVR). 
The PSVR is the most commonly used parameter to objectively measure restenosis. A 
PSVR of >2 is considered significant restenosis and equates to a narrowing of >50% 
of the lumen and is the most commonly used criteria to define restenosis.88
The biggest problem with Duplex is that it is operator dependent and the greater the 
skill of the operator the more accurate the results. Assuming that angiography is the 
gold standard in assessing stenosis, in experienced hands however the sensitivity and 
specificity of Duplex both in identifying and quantifying arterial stenosis is as good as 
an angiogram if not better.89'91 Newer machines with increased sensitivity have over 
come the old problem of assessment in the face of multiple stenosis and in calcified 
vessels. It also has the advantage of delineating plaque morphology which may play a 
role in outcome and prognosis.47
It is however important to differentiate between restenosis and the need for re­
intervention. This has to be a clinical decision based on symptoms and the natural 
history of the problem. Plaque characterisation may help one decide which lesions 
need re-intervention and which don’t. Duplex surveillance of grafts has been used and 
is common practice in a number of units. But its usefulness is not yet established. 
While it picks up treatable lesions earlier it does not affect limb salvage.92'95
Intravascular ultrasound
This is a more recent development in the approach to assessing restenosis. While it 
provides an excellent view of the cross-section of the artery it is not suitable for routine 
use as it is invasive and expensive. In animal models it has shown increased
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knowledge of changes in the arterial wall after intervention. Clinical studies have 
shown benefit in predicting restenosis after angioplasty.96 97
Angiography
Peripheral arteriography has long been considered the gold standard in evaluating 
restenosis. It does provide the most accurate operator independent evaluation of the 
vessel lumen and is easily reproducible to compare with earlier films. However it is an 
invasive procedure with risk of complications. It provides only uni-planar views a 
problem which to an extent has been eliminated by using a C-arm to get multiple 
views. It is also now possible to measure pressure gradients across a lesion, providing 
good information on flow patterns. Angiography is indicated in patients who are going 
to have a endovascular re-intervention and will then be done along with the therapeutic 
procedure. Its use purely as a diagnostic tool in diagnosing and quantifying restenosis 
is limited. It is however routinely done if surgical intervention is planned.
On angiography restenosis is defined by a >50% loss in the gain in diameter achieved 
by PTA or an increase in % diameter stenosis by >30% ffom the post PTA value. 
These measurement have to be made using standard software in order to avoid inter 
and intra-observer variation which have been shown to be significant 9810°. The 
volume and rate of contrast injection also has to be standardised.
MRA and CT angiography.
These non-invasive techniques have made great strides in the last few years and 
provide excellent images for both proximal and distal disease. These are especially
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useful in assessing distal run-off distal to the occlusion and in proximal vessels which 
can’t be assessed on Duplex because of body habitus. At present their main 
disadvantage is cost and availability. The information available on modem Duplex 
machines is so good that they will remain the first investigation in assessing restenosis.
As mentioned in chapter 3 between 35-50% of all femoro-popliteal angioplasties 
restenose in the first year alone. There are various reasons as to why this can happen. 
Obviously there is the category where angioplasty fails almost immediately. This is 
usually due to thrombosis within the vessel. It is important to remember the physical 
changes occurring in the plaque at the time of angioplasty. It is almost inevitable the 
plaque fractures during angioplasty. This exposes the highly thrombogenic material 
within the plaque to blood and it is amazing that thrombosis does not occur in every 
instance. Obviously the increase in luminal diameter results in an increased velocity of 
blood flow which contributes to preventing this from happening. Does this mean that it 
is only those angioplasties that lead to inadequate dilatation in the lumen size that 
thrombose off? Immediate failure is brought about by such factors as a poor run-off 
and poor inflow. Ramaswami et al have recently shown that plaque character plays an 
important role influencing results. They have suggested that the worse the calcification 
and the more radio-opaque the plaques are the greater the chance of failure.47 These 
patients usually need immediate intervention such as thrombolysis or surgery.
Pathogenesis of restenosis
Why do some vessels restenose and others don’t? Is it possible to predict which will 
need intervention and which won’t? Most work has been done on animal models
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with artificially injured artery. The problem with this is that atherosclerotic plaques 
already have VSMCs in them and are bound to have a different biological response to 
the injury model. There is however an atherosclerotic model in rabbits which is 
helping in our understanding of the disease. True restenosis has 2 main causes, intimal 
hyperplasia and progression of disease. It is commonly believed that recurrence in the 
first year is primarily due to intimal hyperplasia and recurrence subsequent to that is 
primarily due to progression of atherosclerosis. Inevitably both processes act in 
tandem to produce lumen loss. The resulting loss in luminal area is exaggerated by the 
process of negative remodelling i.e. shrinkage of the vessel in the long term
Phases of NIH
Very simply put, intimal hyperplasia is an inflammatory response to injury to the 
intima. As in the skin this response can be hyperplastic and can thus do more harm 
than good. Fuster et al divided this process into 3 phases.101 Phase I which is basically 
recoil of the angioplastied vessel occurs in the first 24 hours. Phase II involves the 
formation of a mural thrombus and reorganisation of the connective tissue in the 
ensuing 2 weeks. Phase III can be divide into 3 waves and overlaps with Phase II but 
continues on for 2-3 months.
The first wave seen within 2 days after balloon injury consists of replication of VSMC 
in the media. This is brought about by the release of basic fibroblast growth factor 
(bFGF).102 The bFGF is pre-formed and stored in medial VSMC and released when 
there is medial injury caused by the angioplasty. It may also be present on matrix
68
binding sites in the extracellular matrix and released on injury or by stimulation by 
platelets.
The second wave of response is characterised by the migration of these VSMC from 
their normal position to the intimal layer. This is brought about by platelet-derived 
growth factor (PDGF).103 Arterial injury stimulates the release of plasminogen 
activators. These can cause degradation of proteins in the extracellular matrix along 
with the internal elastic lamina. Injury also releases matrix metalloproteinases (MMP), 
which not only degrade collagen fragments but also cause lysis of elastic fibres. They 
also delay the formation of a neo-intima.104'106
Once in the intima, these VSMC replicate to give rise to the third wave of response. It 
is uncertain as to what exactly causes the mitogenesis. However it is known that large 
quantities of cytokines and leukotrines such as tumour necrosis factora (TNFa) are 
released at the time of arterial injury and these could well lead to the VSMC 
proliferation.45 Simultaneously there is also an increased deposition of extracellular 
matrix in the intima following injury. In fact it may play quite a major role in NIH 
given that restenosis usually occurs over months while VSMC proliferation stops 
within weeks of injury while matrix deposition does not. This theory is further 
strengthened by the fact that VSMC replication in human models is not as frequent as 
injury models. 45
The various growth factors involved in the above waves are secreted by a variety of 
different cells such as the endothelial cells, VSMC, platelets and macrophages which 
are mobilised to the site of injury. Endothelial re-growth also plays a role in
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the regulation of NIH by inhibiting both migration and deposition of VSMC.103’107108 
It also controls vessel tone and platelet aggregation through the secretion of nitric 
oxide (NO).109;110
Remodelling
To these can be added a 4th stage influenced primarily by arterial remodelling. Glagov 
et al showed that the human artery responds to the loss in lumen area associated with 
an atherosclerotic plaque by undergoing adaptive enlargement.111 In fact up to a 40% 
narrowing of the lumen can be compensated by arterial expansion. There is increasing 
evidence that arterial remodelling plays an important role in the eventual outcome of 
angioplasty. It is suggested that the eventual lumen area is dependent more on the 
amount a vessels shrinks after angioplasty than on the extent of NIH. This has been 
bome out by the fact that stenting an artery does not prevent NIH but maintains 
luminal size by holding the vessel open. It is likely that matrix remodelling plays a 
major role in arterial remodelling.
The mechanism causing remodelling has not been clearly demonstrated. It is known 
that the degree of injury caused by the angioplasty influences the eventual lumen 
diameter.112 The degree of balloon injury has been described by Schwartz et a l 46 as 
follows:
Score 0 Endothelium denuded; IEL intact; Media compressed
Score 1 IEL lacerated; media compressed but not lacerated
Score 2 IEL and Media lacerated; EEL intact
Score 3 Media disrupted; EEL lacerated
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The greater the injury score, the more the neo-intima area and larger the whole arterial 
dimension.113 When the net result of this remodelling is overall shrinkage of the artery 
it is called negative remodelling. It is feasible that this is the result of ongoing 
inflammation and scarring in the adventitia following the injury of angioplasty. Thus if 
the injury score is higher although the initial result may be a bigger artery the eventual 
scarring may in fact lead to negative remodelling and restenosis. Remodelling is 
probably mediated by regulation of elastin and collagen by MMPs and TIMPs.114,115 It 
has been suggested that luminal blood flow post-intervention may be a factor in 
determining the extent of remodelling.111 The degree of injury to the vasa vasorum 
during balloon injury may also affect remodelling.
Medical and experimental interventions 
Anti-platelet agents
Although there are no randomised controlled trials showing an advantage of aspirin 
over a placebo in preventing restenosis Schwartz et al has shown a small beneficial 
effect with aspirin.116 Minar et al randomised 216 patients into 2 groups one getting 
lOOOmg of aspirin, one getting lOOmg of aspirin and showed no difference in the 2 
groups in terms of restenosis although compliance was better in the low-dose group 
which also had lesser complications.117 However, independent of this effect, the 
proven benefits of preventing cardiovascular morbidity and mortality should prompt 
every patient to be put on at least 75-150 mg of aspirin daily. Recent additions to this 
group including ticlopidine and clopidogrel, which again have shown benefit in 
preventing cardiovascular events both independently and in conjunction with aspirin.
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These may also play a role in the prevention of restenosis.32 
Anti-coagulants
Heparin is widely used both during percutaneous and surgical vascular procedures and 
its role cannot be overemphasized in preventing thrombosis. However its long-term 
role in the prevention of NTH has not been established. There is no evidence to suggest 
that warfarin, in spite of its anti-thrombin effect, is effective in preventing restenosis.
ACE inhibitors.
Although Angiotensin converting enzyme (ACE) inhibitors have been shown to 
inhibit VSMC proliferation in vitro and in vivo in animals, ACE inhibitors have been 
shown not to have any effect in preventing restenosis in a clinical setting.
Antiproliferative therapy and gene therapy.
As already mentioned growth factors play an important role in the development of 
NIH. These growth factors commonly act by stimulating surface receptors, which in 
turn stimulate the secretion of mitogenic proteins, or by directly modifying oncogenes 
within the cell. Thus there can theoretically be a 2-pronged attack on this activity. 
Antiproliferative agents act by blocking the effect of the growth factors either by 
inhibiting them directly or by blocking the growth factor receptors. The other mode of 
attack would be to inhibit gene expression. The problems with these methods are two
fold. No suitable animal models are available to recreate an atherosclerotic model to
118test it on. Secondly presently available delivery systems are very inefficient.
The systemic therapies used against restenosis are summarised in Table 4.1
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Generic therapy Specific examples
Anti-platelet drugs Aspirin, dipyridamole, Ticlopidine
Anti-coagulants Heparin, warfarin
Anti-inflammatories Dexamethasone, prednisolone
Anti-oxidants Probucol Lazaroids
Antibodies Anti-platelet, anti-CD 18, Anti-PDGF, Anti-FGF
ACE inhibitors Captopril
Calcium-antagonists Nifedepine, Diltiazem
Immunosuppressant Azathioprine, cyclosporine
Matrix modulators Collagen synthetase inhibitors
Endothelial modulators Prostacyclin E2, L-Arginine
peptides TGF-p, interferon y, somatostatin
Receptor antagonists Prazocin, losartan, ketanserin
Table 4.1 Systemic therapies used to reduce restenosis
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Interventional techniques.
We have already talked about the use of stenting in the previous chapter. However it 
has been shown that stenting does not prevent NIH. The neointima tends to grow over 
and through the stent and incorporates itself within it. The stent works on the principle 
of providing a scaffolding to hold the lumen open thus giving credence to the 
hypothesis of vascular remodelling. Similarly atherectomy devices and laser 
angioplasty have been attempted to prevent restenosis, none of which have been found 
to be useful.
Brachytherapy
Brachytherapy is the use of intra-luminal radiotherapy as an adjuvant to angioplasty 
and stenting in order to prevent restenosis. It does so both by inhibition of VSMC 
proliferation as well as promoting positive remodelling. It prevents late vessel 
constriction by either reducing collagen and matrix production, or thinning of the 
residual plaque and media. Intra-luminal radiotherapy is delivered by either catheter- 
based devises or by radioactive stents. The radiotherapy is provided using radioactive
90 192isotopes such as yttrium-90( Y) providing (3-radiation and iriduim-192 ( Ir) 
providing y radiation. While this has been tested extensively in the coronary circulation 
there have been very few trials in PVD. This is discussed in greater detail in the next 
chapters.
It is however not without problems. There have been several reports of early late 
thrombosis at 24-72 hours. Another major problem is that of edge restenosis when 
there is an increased neointimal response at the edges of the area radiated. The doses
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of radiation used are not yet standardised ranging from 5Gy to 25Gy. It is still not clear 
as to which form of radioactivity is better. Doubts have also been cast as to the long 
term effects of radiotherapy on the vessel wall, the fear being that there will be 
aneurysmal change and even vessel blow-out. Further the carcinogenic effect of the 
radiation is unaccounted for. 119120
Coated stents
In the last five years there has been renewed interest in the use of coated stents as a 
means of preventing in-stent restenosis. This interest has been stimulated by the use of 
Rapamycin (sirolimus) and paclitaxel, agents which were previously used as 
chemotherapy for certain cancers. Sirolimus has weak antibiotic properties but it acts 
primarily by being an immune modulator and inhibiting the effects of growth factors 
described in the earlier chapter. It does this by inhibiting kinase pathways responsible 
for RNA translation thus inhibiting formation of proteins essential for VSMC 
migration and proliferation.121 Paclitaxel is an anti-proliferative agent which 
specifically inhibits the G2 /M phase of cell division.119122 During the period of 
writing up of this thesis it has become obvious that drug eluting stents are proving to 
be extremely effective in inhibiting restenosis. This has been shown in a number of 
trials and seems to be heading towards first line treatment of coronary artery occlusive 
disease. They have not yet proven their place in PVD and results for this are 
forthcoming.
Photodynanuc therapy. (PDT)
PDT is a novel technique in which application of light at particular frequency to a 
previously loaded photosensitive drug leads to activation of the drug, release of
75
highly reactive free radicals and hence cell death. PDT has been used for tumour 
ablation and palliation in oesophageal, colonic, bronchial and oro-pharyngeal 
malignancies. In the last 10 years we have pioneered the use of PDT in tackling this 
problem. PDT has been shown to cause VSMC and endothelial cell death by apoptosis 
which in turn leads to inhibition of restenosis. The cell loss is temporary and there is 
endothelial repopulation in 3-7 days and VSMC repopulation with in 14-28 days in 
animal models. There is no inflammation in the vessel and no apparent long-term 
effects to the vessel wall. My work in this thesis deals with the application of PDT to 
restenosis and in-stent restenosis. It is discussed in great detail in the next chapter.
Stenting and In-stent restenosis
As already mentioned in the previous chapter stenting is a commonly used adjuvant to 
PTA. About 85% of coronary angioplasty is accompanied by stenting and over 50% of 
iliac angioplasty is accompanied by stenting. Stenting is used as a means of preventing 
restenosis as well as for the treatment of it. However as previously mentioned stenting 
does not prevent NIH. It acts by maintaining lumen diameter and preventing negative 
remodelling. It is clear that that the processes involved in in-stent restenosis are similar 
to stenosis following standard angioplasty. It is also apparent that there are clear 
differences between the two both in pathophysiology and outcome. The main 
difference in the physiology is the prolonged nature of the injury response in stenting. 
The greater the reactivity of the stent, the poorer the outcome. All the phases of 
restenosis last for much longer especially phase 3 i.e. proliferation of the VSMC once 
they have migrated to the intima. There is also evidence of a more chronic
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inflammatory response with the presence of foreign body cell around the stent struts 
and the presence of more lymphocyte, histiocytes and eosinophils. In addition 
endothelial regeneration is restricted at the site the stent struts. There is also clear 
evidence that the expansion and outward pressure created by the stent struts on the 
vessels wall can create relative hypoxia in the vessels wall which contributes to the 
inflammatory and repair process. All of these effects are however well countered by its 
positive effect of wall remodelling. By acting as scaffolding it offsets the lumen 
narrowing effects of the above processes and hence provides a better clinical result. An 
ideal stent would be one which can counteract the N1H stimulating properties of 
ordinary stents.
Conclusions
It is clear that restenosis is a significant problem both in the coronary and peripheral 
circulation accounting for significant morbidity and mortality. The cost of 
revascularisation in Britain is £ 8800/patient while that of amputation and the 
rehabilitation that goes with it, is >£ 25000/patient. At present there is no completely 
effective way of treating or preventing restenosis. Stenting reduces restenosis 
especially in the coronary circulation but does not prevent NIH. Drug eluting stents 
seem to show very good medium term results, but there have been concerns about long 
term complications because like brachytherapy, sirolimus causes permanent loss of 
medial and intimal cells. PDT may provide some of the answers in this battle.
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Chapter 5. Photodynamic therapy (PDT)
Photodynamic therapy can be defined as the use of light in order to activate a 
photosensitive drug in the presence of oxygen in order to treat a disease or disorder.
History of PDT
The therapeutic properties of light have been known to exist for many millennia. For 
example extract of Psoralea corylifolia, now known as furocoumarins, followed by 
exposure to sunlight was used to treat vitiligo. Hippocrates advocated the use of 
sunbaths for treating wasted muscles. The solarium for sunbathing was very popular 
among the ancient Greeks and Romans and there is evidence to suggest that it was 
used by the ancient Egyptians as well.
The first modem scientist to advocate the use of light for treatment was Niels Finsen 
who treated lupus vulgaris using light from a carbon arc with a heat filter. Further it 
was used to treat scarring following small pox. He was awarded the Nobel Prize in 
1903 and is regarded as the father of phototherapy.
Oscar Raab a medical student in 1900 was the first to describe the tissue-destroying 
effects of light in the presence of a photosensitiser. He showed that acridine killed
1 9Tparamecia in the presence of sunlight. Von Tappeiner and Jodlbauer who first 
showed that oxygen was necessary for this effect coined, the term ‘photodynamische 
Wirkung’ translated into photodynamic action or effect.124 Through the 20th century 
there have been a number of contributors to the understanding of PDT, none more than 
Meyer-Betz, who proved the photosensitivity of porphyrins by injecting
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himself with it and exposing himself to light from a Finsen lamp as well as sunlight 
and showing severe photosensitization due to it.125
It is only since the 1960s that the therapeutic potential of PDT has been exploited. 
Lipson demonstrated that haematoporphyrin derivative (HpD) produced fluorescence 
in human tumours and was used for treating a patient with a recurrent ulcerating breast 
cancer.126 Diamond demonstrated tumour necrosis in experimental gliomas in rats 
using HpD and visible light.127 Thomas Dougherty, who is a doyen of PDT treatment, 
was the first to report a 48% cure rate in rats and mice with sub-cutaneously implanted 
tumours. He was also the first to report encouraging results in a clinical trial with 25 
patients with metastatic, cutaneous and subcutaneous tumours.128
The physics of PDT
PDT requires three essential components to be effective, light, a photosensitiser and 
oxygen. Application of these three components in an appropriate combination 
produces tissue destruction. What makes PDT especially useful is that it produces 
healing without significant scarring.
When a photosensitive drug is subjected to light of a suitable wavelength it becomes 
activated from a ground state into an unstable excited state. Figure 5.1. This is an 
electronically excited state called a triplet state. This has an extremely short half life in 
the range of 10‘3 s. This triplet state can undergo 2 types of reactions: It can react 
directly with the substrate i.e. the tissues by hydrogen ion or electron transfer to form 
free radicals, which interact with oxygen to produce oxygenated products. This is
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known as a type I reaction. Alternately it can transfer its energy to oxygen directly to 
form highly reactive singlet oxygen '0 2, which reacts with the tissue substrates to 
produce its effects. This is known as a type II reaction.
These 2 reactions may occur simultaneously and to varying extents depending on the 
photosensitiser substrate and the oxygen concentration. There is however evidence to 
suggest that most of its effects are caused by singlet oxygen generation. Optimally an 
oxygen concentration of >5% is needed. However effects can be seen at 
concentrations as low as 1%.
The first step in PDT is delivery of the photosensitiser to the tissue. The key issues 
here are the selectivity of the sensitiser for the target tissue and the doses needed to 
attain optimum concentration. Each photosensitiser has its own pharmacokinetic 
profile. It has been found that tissues with a high concentration of reticulo-endothelial 
cells tend to concentrate photosensitisers. Thus the liver has one of the highest 
concentrations in the body while the muscles have the lowest. Some sensitisers do tend 
to concentrate in tumour tissue. Selectivity can be achieved by the timing of delivery 
of light as the drug tends to be concentrated at varying times in varying tissues. Using 
the pharmacokinetic and pharmacodynamic curves of the drug-light interaction, 
optimal times for light delivery following drug administration can be selected. One of 
the ways selectivity can be achieved is by isolation of the tissue to be illuminated. 
While this is possible in surface PDT such as on skin lesions it is virtually impossible 
in deep tissues such as gut and blood vessels. Another method that is being tried is 
tagging the sensitisers with markers such as antibodies to the target tissue. To an
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extent however the need for selectivity is superfluous. As mentioned before, one of the 
key features of PDT is that it heals with minimal scarring, so that even if normal 
surrounding tissue is affected there are usually no long-term sequelae. Sensitisers can 
be classified as follows.129
First generation photosensitisers.
Haematoporphyrin derivative (HpD)
HpD was one the first agents used for PDT since the 1960s. It is not a pure compound 
but a mixture of haematoporphyrin (Hp), protoporphyrin and a range of intermediate 
dehydration products. It is prepared by treating Hp with acetic acid with sulphuric acid 
as a catalyst. This is then dissolved in a solvent base. Because of the lack of quality 
control in producing HpD a more standardised and refined derivative is used in 
practice.
Photofrin
Photofrin was the first drug to get FDA approval for use in PDT. It is a refined and 
standardised form of HpD with the monomers and the unstable component of HpD 
removed. Light at the wavelength of 630nm in the red end of the visible spectra is used 
to activate it. It is however not without its drawbacks. Its efficiency in producing 
cytotoxic effects is low. The wavelength of light it requires has very little tissue 
penetration. It remains in the skin for 3-4 weeks if not months thus causing the patient 
to be photosensitive for a long time necessitating the avoidance of direct sunlight or 
bright lights. However it has the benefit of being time tested. It is commonly used in 
the treatment of head and neck, oesophageal, bladder and lung cancer. It
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has also been successfully used in pre-malignant lesions such as Barrett’s oesophagus 
and oro-pharyngeal dysplasias. It has also been used in brain tumours such as 
glioblastomas and astrocytomas.130
Second generation photosensitisers
These photosensitisers were developed in order to overcome the above mentioned 
drawbacks of Photofrin. Light sensitisation in the red and infrared region leads to a 
much higher tissue penetration. This is primarily because of higher absorption of 
green, blue and ultra-violet light by the haemoglobin in the blood. Most of the second- 
generation sensitisers are activated most effectively by light in the red and near- 
infrared wavelength.
Chlorins and chlorin-type sensitisers 
NPe6, an aspartyl derivative of chlorin-e6, and meta-tetrahydroxyphenol (m-THPC) or 
Foscan are the commonest 2 used in this group. NPe6 is a highly water-soluble 
compound with rapid clearance which reduces the incidence of cutaneous 
photosensitivity. It is activated by light at 664nm. It has been used in the treatment of 
various cancers such as head and neck, lung cancer, bronchial oesophageal cancer, 
bone and liver secondaries and in gynaecological conditions. It has more recently been 
tested for use in vascular PDT with good inhibition of NIH. 131
Foscan is sensitised at multiple wavelengths, but the 652nm is the commonly used one 
as this provides maximum tissue penetration. It has been used in experimental models 
of head and neck cancer, skin cancer and oesophageal cancer along with liver 
secondaries. Photosensitivity of the skin lasts for at least 2-3 weeks. It is now
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licensed for use in Europe for advanced head and neck cancers.
Phthalocyanines
Aluminium disulphonated phthalocyanines (ASP) and Chloroaluminium 
disulphonated phthalocyanines (CASP) have both been used as photosensitisers and 
have shown efficacy in inhibiting VSMC proliferation and NIH. Phthalocyanines are 
synthetic porphyrins-like compounds which can chelate with a number of heavy ions 
such as aluminium and zinc which enhance photo-activity while others such as copper 
and cobalt which reduce it. ASP and CASP have the good absorption at a longer 
wavelength of 675nm and hence a greater depth of tissue is affected by the PDT 
effects. Again compared to 1st generation photosensitisers they have better clearance 
due to higher water solubility and hence less cutaneous photosensitivity.132133
5-aminolaevulinic acid induced protoporphyrin IX
5- aminolaevulinic acid (ALA) is an endogenous compound formed from glycine and 
succinyl CoA in the first step of biosynthesis of haem. (Figure 5.2) Protoporphyrin IX 
(PP9) is a compound further down the process of haem synthesis a step before the 
formation of haem itself. If ALA is added in excess to this system then the negative 
feedback loop whereby haem inhibits ALA synthetase is bypassed. The next rate 
limiting step in the process of haem production is when PP9 is converted to haem by 
ferrochelatase. Hence when excess ALA is administered there is accumulation of PP9. 
The amount of PP9 produced in individual cells may vary with accumulation products 
further up the process accumulating instead. Although PP9 is best activated by light at 
410 nm the distinct lack of tissue penetration at this wavelength restricts its
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Figure 5.2 Pathway of Haem biosynthesis
Haem has a negative feedback affect on the formation of 5-ALA which 
is bypassed by adding exogenous ALA.
Addition of ferrochelatase inhibitors delays the breakdown of PPIX to 
haem.
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use at this wavelength. Optimum tissue effects are produced by using light at 635nm 
first described by Kennedy et all in 1990 for treatment of 80 basal cell carcinomas.134 
Following these there have been a number of studies showing the efficacy of ALA 
PDT for cutaneous lesions.135
ALA can be administered orally, intra-venously (IV) as well as topically. It has a short 
drug light interval which can be 1-2 hours if it is administered IV and 4-6 hours orally. 
It excreted in 24-72 hours with skin photosensitivity lasting only 24 hours. It has 
favourable tumour: normal tissue fluorescence pattern which together with its 
photobleaching properties allows limitation of damage to normal tissue. Although it 
concentrates in normal tissue it does show some selective uptake in mucosa compared 
to muscle in conditions such as Barrett’s oesophagus and oral cavity lesions.136 
137However the depth of its effects is only 2 mm from the surface and hence its use is 
restricted to mucosal conditions only. This is because of a combination of limited 
depth of penetration of 635nm light, as well as preferential concentration of PP9 in
1 ^ Q .  1
superficial tissue. This is however an advantage in the blood vessels where its 
effects are only desired up to 2 mm. In sensitive tissue such as the myocardium this 
prevents any deeper damage. The limitation of this is that it cannot be used for 
treatment of invasive cancers.
ALA PDT has been used in number of different applications such as oral lesions, 
bronchial and oesophageal lesions, gastric lesions, skin lesions, bladder lesions135,139' 
142. A number of different agents have been used in order to enhance the effects of 
ALA. Inhibitors of ferrochelatase and protoporphyrinogen oxidases potentially
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increase PP9 concentration along with iron chelation135 143 144
Long chain ALA ester derivatives have recently been used to increase bio­
availability.145 IV ALA allows higher doses to be used without increasing hepatic 
toxicity by reducing first pass metabolism.
Light delivery and tissue distribution
Light fluance in tissue is attenuated by optical absorption of both the target tissue 
(mainly due to haemoglobin), the sensitiser itself and by optical scattering. Hence the 
haemoglobin content of tissue influences the light penetration in that tissue. Moreover, 
although in general, absorption of light by the sensitiser itself is much lesser than the 
tissue itself, for some sensitisers such as phthalocyanines, light absorption can be quite 
high, leading to a phenomenon known as ‘self-shielding’. The wavelength of light 
used also influences the degree of tissue penetration as lower wavelengths have higher 
scatter and more absorption and hence lower penetration. Hence tissue penetration is 
1-3 mm at 630nm while it is double that at >700nm146. Hence the depth of effects is 
greater with sensitisers which are activated at longer wavelengths.
Numerous light sources have been used for PDT. Although broad spectrum light 
sources can be used it is more efficient to deliver light of the specific wavelength. The 
only absolute is the delivery of the relevant wavelength for the given sensitiser. Lasers 
and LEDs provide a good source of wavelength specific light while fluorescent tubes 
and incandescent lamps are broad spectrum. Broad spectrum devices are cheaper and 
used to be more portable. It is advantageous with ALA as some of the photoproducts 
produced when PP9 is activated are also photosensitive at 670nm. However their
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application is restricted to surface application. Moreover infra-red light is also 
generated leading to hyperthermia and heat damage.
Lasers are now easily available in a solid-state and portable form and are used very 
commonly. The biggest advantage of using laser is the application of light at a distant 
or internal target by use of optical fibres. These have been variously used in gastro­
intestinal tract and in vascular disease. The biggest drawback is the cost which is high. 
Old metal vapour dye lasers (copper, gold) are now replaced by diode laser which 
gives a consistent output and are user-friendly. LEDs are a new development in PDT 
and could provide a cheaper source of monochromatic light.147
There is now evidence that a break in light transmission allows for greater PDT effects 
of tissues. This is called fractionation of light and usually involves a window of 1 
minute after part of the light delivery. Fractionation allows the re-accumulation of 
oxygen in the tissue and specifically when using ALA for re-accumulation of PP9. 
Animal data suggest that the optimum time for fractionation is after 20% of the light 
has been delivery. It is probably not effective later as micro-vascular damage precludes 
the mechanism.148150
Clinical applications of PDT
PDT has been used in the treatment of many malignant and pre-malignant conditions 
and a few benign conditions. The real advantages of PDT are lower morbidity rates, 
improved functional and cosmetic outcome and relative simplicity of use. There are 
now Phase ITb studies on large number of patients showing efficacy in both palliative
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and curative treatment. However most of the data consists of anecdotal reports or small 
series. The main difficulty is achieving adequate necrosis of large solid tumours due to 
limited light penetration. Hence its usefulness as a curative treatment is much better for 
surface malignant and pre-malignant lesions.
The majority of use is in surface lesion both on the skin and mucosa of hollow organs. 
Pre-malignant conditions of the oro-pharyngeal cavity, Barrett’s oesophagus with high 
grade dysplasia, and carcinoma-in-situ of the lung and bladder have been treated 
effectively with PDT using various sensitisers.151'153 Compared to radiotherapy and 
radical surgery, PDT offers a much better functional result with very little morbidity. It 
also has the advantage of being used repeatedly with few long term sequelae.
Malignant lesions of the skin such as Basal cell carcinoma are better treated with PDT 
in areas where wide resection can give a poor functional result. Similarly it has been 
used successfully in the treatment of Bowen disease.154,155 It has been used for 
curative treatment of early oesophageal and lung cancer as well as superficial bladder 
cancer.156"158 Its role in the palliation of advanced forms of these cancers is also well 
established. Photofrin PDT has also been shown to extend symptom free survival in 
cholangiocarinomas.159 Interstitial PDT with Foscan has also been used with limited 
success by feeding light fibres into solid tumours through needles placed with image 
guidance. Using a pull back technique and multiple fibres substantial tumour necrosis 
can be achieved.
The FDA has approved the use of Visudyne PDT for age-related macular degeneration
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of the eye where it has shown excellent results.160 
PDT in vascular disease
Both external and endovascular illumination of photosensitised blood vessels causes 
rapid loss of endothelial and vascular smooth muscle cells131’161'163. As early as 1982 
Spears et al demonstrated the concentration of Haematoporphyrin derivative (HpD) in 
atherosclerotic plaques.164 They were the first to demonstrate fluorescence 48 hours 
following administration of HpD in the aorta of rabbits fed on a high cholesterol diet. 
The potential implications of this were largely ignored until the early 1990s.
Both Ortu et al, from Boston and Nyamekye et al ffom our own centre demonstrated 
significant inhibition of NIH in the rat carotid using different photosensitisers i.e. 
Chloroaluminiun-sulphonated phtalocyanine (CASP), and 5- Aminolaevulenic acid 
(5-ALA) respectively.162,163 Both experiments showed that application of PDT to 
balloon injured rat carotid arteries showed no NTH at 3 and 7 days. This has been 
confirmed by a number of articles using different photosensitisers such as Gonschior et 
al with Photofrin, Woodbum et al with Motexafin Lutetium and Nagae et al with 
Mono-L-Aspartyl-Chlorin e6 (NPe6).131,165 166 Table 5.1 summarises work with 
different photosensitisers used in vascular PDT.
This was followed by work by Grant et al from our centre looking at the integrity of 
rabbit carotid arteries after PDT using CASP and 5-ALA.167 Rabbits were sacrificed at 
3, 7 and 21 days after vascular injury and PDT to the carotid artery. The isolated 
carotid segment was then subjected to hydrostatic distension till bursting. Compared to 
controls the PDT treated segment at all 3 time points required higher pressures
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Author Year Photosensitiser Animal/Clinical Findings
Spears et al 1982 HpD Rabbits/Monkeys Concentration of HpD in plaques
Gonschior et al 1991 Photofrin Human Uptake in atherosclerotic plaque
Ortu et al 1992 CASP Rat Inhibition of NTH
Grant et al 1994 ALA Rat Loss of endothelium and VSMC
Nyameke et al 1995 A1S2Pc Rat Inhibition if NIH
Jenkins et al 1998 ALA Pig Inhibition of NIH + positive remodelling
Jenkins et al 1999 ALA Clinical Clinical safety and feasibility
Rockson et al 2000 Antrin Clinical Clinical feasibility and safety
Nagae et al 2001 NPe6 Rabbit Inhibition of NIH Endovascular light application
Table 7.3 Major studies using Vascular PDT for restenosis
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before bursting showing that PDT actually increased the structural integrity of the 
arterial wall. It has subsequently been shown that PDT causes physiological and 
structural changes in the collagen in the extra-cellular matrix. Various collagenases 
such as Matrix metalloproteinases and urokinase like collagenases are released at the 
time of intimal injury occurring during angioplasty. These have been shown to be 
inhibited by PDT. PDT has also been shown to increase cross-linkages in Type I 
collagen not only between collagen to collagen but also between collagen and 
albumin. This is probably the reason the structural strength of the vessel increases after 
PDT.
PDT has also been shown to be responsible for inhibiting the migration of VSMC 
from the media after balloon injury.168'171 The next step was to show similar effects in 
higher animals such as pigs where the anatomy and structure is similar to humans. 
Jenkins et al from our centre showed that these effects could be duplicated in porcine 
coronary and iliac vessels.161172 In a first set of experiments they demonstrated the 
concentration of PP9 in the vascular media 4-6 hours after intravenous injection of 5- 
ALA. They also showed that complete cell ablation could be achieved with a dose of 
60mg/kg 5-ALA and a light dose of 50 J/cm2 of 635nm red light using a copper 
vapour pumped dye laser. In a second set of experiments porcine coronary and iliac 
arteries were balloon injured and exposed to endoluminal PDT. A 0.2mm core 
diameter optical fibre with a 4cm diffuser tip introduced through the guide-wire 
channel of a balloon catheter was used for illumination of the angioplasty site under 
Image-intensifier guidance. Transparent balloons used for brachytherapy were
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modified for use in these experiments. Following PDT there was complete cell 
ablation at 3 days. At 28 days there was complete re-growth of the endothelium with 
some re-growth of the medial cell. Further at 28 days the area within the External 
Elastic Lamina and the luminal area in PDT treated arteries was significantly more as 
compared to controls. The VSMC cell count was also much less in the PDT treated 
arteries although it just failed to reach statistical significance. This clearly showed that 
PDT promoted positive arterial remodelling over and above the effects of cell ablation.
It is now established that PDT has a number of favourable effects as an adjuvant to 
angioplasty. As opposed to brachytherapy it does not completely stop regeneration of 
the cell. In fact the complete regeneration of the endothelium suggests that the risk of 
late thrombosis is reduced if not absent. Later experiments in our own centre, 
following pigs to 56 days has shown no late thrombosis. Also compared to 
brachytherapy where there is a theoretical risk of wall weakening and rupture, PDT 
actually increases wall strength.
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Chapter 6. Aims of Thesis
Models of arterial injury
The advantages, disadvantages and limitation of various animal models of restenosis 
have been extensively reviewed While the rat carotid, rabbit carotid and iliac and 
porcine coronary, carotid and iliac vessels have been used each has its innate 
advantages and disadvantages.173'176
The rat model has been extensively used as a model of arterial injury and PDT
133 162" 163" 177 •work. ’ It is cheap, easily supplied and housed and relatively easy to handle.
Its small size however precludes the application of and conclusions from this model to 
humans. The small size creates a vast weight and drug dose differential compared to 
humans. The small size of the vessels which are in the order of 1-2 mm makes the use 
of any endovascular devices difficult. Most importantly the response to balloon injury 
and by corollary stent injury appears to be limited to VSMC proliferation which is 
overly sensitive to pharmacological and other forms of therapy.
The porcine arteries have provided very good models because of tackling the said 
disadvantages in the rat model. 3 different arteries can be used the coronary, carotid 
and iliac allowing the use of more than one vessel in an animal. The size also allows 
the use of endovascular devices such as angioplasty balloon, stents and light deliveiy 
devices with very little modification from the ones used in humans.161165 The response 
of the vessels is closer to that seen in balloon injury in humans with elements of 
VSMC proliferation, deposition of extra-cellular matrix and arterial remodelling.
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However there are problems with handling of pigs. They are extremely sensitive to 
any cardiac intervention and very easily develop ventricular fibrillation and asystole 
leading to death. They are a large animal which makes them expensive and difficult to 
handle. The incumbent Foot and Mouth disease also made the transfer and handling of 
pigs more complicated.
The rabbit model is a good compromise. It is a relatively small animal, easy to handle 
and reasonably cheap. Both the rabbit carotid and iliac have been shown to be useful in 
creating balloon injury.131,174’176,178 Recent advances in endovascular devices allow the 
use of human devices of a smaller size and very little modification to be used in the 
rabbit. New light delivery devices which are sturdier than ones previously used also 
make the duplication of these procedures in rabbits easy. The injury response seen in 
these animals is also similar to the human response. Stenting in the rabbit iliac and 
carotid is an easy procedure and has been used before to create models of in-stent 
restenosis. It also possible to predictably create an atherosclerotic plaque in the rabbit
1 '70 - 1 fi/1model . It is for these reasons we chose the rabbit as an appropriate model for our 
experiments.
It is important to note that no animal model fully duplicates the complex processes that 
lead to atherosclerosis and restenosis in humans. The atherosclerotic models alluded to 
in the previous paragraph do differ from human plaques in issues such a cell make and 
content, presence of inflammation, deposition of ECM and the progression of the 
plaque. The oversized stent model that I have used in my work, while providing a 
good idea of the response of individual cells and matrix in the animal model, does
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differ from human models. Not in the least because in humans the presence of a 
plaques alters the response. Ultimately the proof for all these techniques lies in their 
effective clinical application.
Method of injury
In-stent restenosis has been effectively duplicated in models such as the rabbit iliac 
and the pig arteries.173 175 Generally over-inflation of the stent by a ratio of 1.2-1.3 with 
the artery is sufficient to stimulate a consistent response. This includes migration of 
VSMC in to intima and proliferation leading to a neointimal plaque. The injury 
response in in-stent restenosis differs from that following balloon injury in being more 
chronic as that stenting provides a more prolonged stimulus.
Photosensitisers
A number of different photosensitisers have been previously used in arterial PDT work 
including Photofrin, other HpD preparations, phthalocyanines, Antrin, NPe6 and 
I3i;m,i62;i66,i78,i8i photofrin and phthalocyanines have the disadvantage of
prolonged photosensitivity which would make them less practical for clinical use in 
the context of restenosis and in-stent restenosis prevention. Both are potent 
photosensitisers and may cause deeper effects when used endoluminally leading to 
affects on neighbouring tissue such as cardiac muscle. Local delivery of Photofrin has 
been investigated in order to eliminate skin photosensitivity but this introduces 
technical and equipment complexities of local drug delivery prior to light 
application.165182
ALA has a number of advantages which make it ideal for use in arterial PDT. It is
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not a highly photosensitive drug. It has a half life of only 10 hours and eliminated in 24 
hours. This means direct sunlight should be avoided only for 24 hours. As peak 
concentrations in the humans are achieved at 5-7 hours in the event of any post­
procedure complication, re-intervention such as surgery can be done within 2-3 hours 
without risk of significant tissue damage from ambient light. The tissue response 
following endoluminal ALA-PDT is only 2-3 mm deep reducing the risk of any injury 
to the surrounding structure on light application. ALA has been used both in animal 
models such as rabbit, rat and pig with success and has also been used safely in human 
studies as well. The drug can be administered orally or intra-venously simply by 
dissolving it in distilled water or saline. 161 >162’167 
Light delivery
In order to simulate clinical application appropriate sized balloon catheters and optical 
fibres were essential for use in the rabbit model. While endovascular devices have 
been used in the porcine vessels in the past there is only one study using endovascular 
light delivery using optical fibres. These were used in conjunction with angioplasty 
balloons. As these are deployed flush to the arterial wall they remove any layer of 
blood between the arterial wall and the optical fibre. Any blood would absorb the light 
and reduce light delivery to the vessel wall. The key requirements for light delivery in 
rabbit artery are a balloon catheter of the appropriate size, with a transparent core for 
diffusion of light and an optical fibre which fits easily in the guide wire channel of the 
catheter. Occum® made a special catheter with 3 mm X 2cm balloon with a 
transparent core. The catheter was 3F so as to easily fit within the rabbit femoral 
artery. It had radio opaque markers at both ends of the balloon to align the catheter
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with an image intensifier. It has guide wire channel of diameter 500 microns capable 
of accommodating a 200 micron optical fibre. A custom-made 200 micron fibre with a 
2 cm diffuser flanked by 2 radio opaque markers was supplied by Pioneer Optics 
which could be aligned with the markers on the balloon. The optical fibre was 
preloaded in the catheter and after alignment the balloon was inflated to just over 
100mm of mercury to cause occlusion of the artery with out any injury. This also 
allowed centralisation of the optical fibre within the artery facilitating uniform light 
delivery to the entire circumference of the artery.
Equipment for light delivery in the clinical project was more easily available. An 
optical fibre with a core diameter of 400pm was used which fit into the central channel 
of a conventional angioplasty balloon modified to have a transparent core and balloon
Thesis aims 
Experimental work
Previous work has established that PDT can inhibit NIH that results from arterial 
injury. While there is some experimental work in the use of PDT as an adjuvant to 
stenting it has never been shown to inhibit in-stent restenosis. In my thesis my 
objective was to apply and optimise the use of PDT as an adjuvant to stenting in order 
to inhibit in-stent restenosis. My hypothesis is that light for PDT can be delivered 
percutaneously along with stenting of the artery and that it will inhibit in-stent 
restenosis when used optimally.
With this in mind ALA was chosen as the photosensitiser as it is converted to PP9 and
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can be activated in 3-5 hours and has minimal photosensitivity for 24 hours. ALA 
PDT has previously been shown to inhibit restenosis and NIH. An experimental small 
animal -  New Zealand White rabbit was proposed as representing an optimum model 
in terms of size availability and response to stenting. Stenting and light delivery was 
performed endovascularly under image intensifier guidance. The first series of 
experiments were aimed at estimating cell loss at 3 days in the intima and media using 
light delivery before and after stenting. The vessels were subsequently harvested and 
sectioned and VSMC counts carried out to estimate cell loss. These were followed by 
experiments to look at neointimal response at 28 days again with light delivery before 
and after stenting. Stented vessels with no PDT were used as controls. On culling the 
relevant sections of stented vessels were harvested and appropriately sectioned. 
Accurate morphometry was performed to estimate arterial dimensions and neointimal 
area and thickness.
Clinical work
The clinical work included 2 projects.
My predecessors in the department had completed a pilot study looking at the effect of 
ALA-PDT as an adjuvant to Angioplasty in 7 patients and published the follow-up to 
6 months.183 With this data base available the next step was to establish long-term 
follow-up. The initial study had shown the absence of any short-term complications 
and had published excellent results at 6 months. As 4 years had passed since the 
original study my aim was to follow-up these patients looking at development of any 
long-term complications and the outcome of the lesions that were treated.
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Given the encouraging results of the pilot study and that the long term follow-up also 
showed good results a randomised controlled trial was conducted. Patients with 
symptomatic lesions in the superficial femoral artery were divided into 2 groups 
comparing standard angioplasty with standard angioplasty and adjuvant ALA-PDT. 
The patients were followed up with regular assessments up to 6 months specifically 
looking at clinical feasibility, safety, and restenosis rate.
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Chapter 7. PDT as an adjuvant to stenting -  
experimental studies
Photodynamic therapy (PDT) is a technique of achieving cell death and tissue loss by 
activation of a previously administered photosensitive agent by light of a specific 
frequency shone upon the target tissue. On application in the artery wall both by 
endovascular and external sources there is almost complete elimination of medial and 
intimal cells by apoptosis. This results in significant inhibition of restenosis after 
angioplasty as well as a significant increase in luminal area. PDT has also been shown 
to promote positive remodelling. In the USA and Europe almost 70-80% of coronary 
angioplasties are now stented. In order to make this technique attractive to use along 
with stents a similar effect needs to be duplicated when PDT is used as an adjuvant for 
stenting.
The aims of this study were 1. To examine the effects of PDT when used an adjuvant 
to stenting as a prophylaxis against in-stent restenosis in the rabbit iliac model. 2. To 
optimise the effects of PDT with stenting in causing intimal and medial cell death and 
inhibiting NIH.
Materials and methods 
Animals and surgical techniques
All animals were treated in accordance with the Animals (Scientific Procedures) Act 
1986 under project and personal licences approved by the Home Office (UK 
Government).
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New-Zealand White rabbits (n=32) 2.5-3 kg were used. The arrangement of the 
operating room is shown in figure 7.1 The rabbits were anaesthetised using Hypnorm 
(Fentanyl/fluanisone) 0.5ml/kg (Janssen) and Hypnovel (Midazolam) 0.05ml/kg 
(Roche) for induction and maintained with inhalation anaesthesia using halothane. 
Following skin preparation, the superficial femoral artery was exposed and bathed 
externally in papaverine (Martindale Romford) for 2 minutes. Figure 7.2 An 
arteriotomy allowed insertion of a 2F cannula and an angiogram delineated the 
anatomy of the aorta and the iliacs. Angiographic images were obtained using a 
Siemens S2000 C arm image intensifier with a road mapping facility, which allowed 
accurate intravascular positioning, and recorded on super VHS video tape. Figure 7.3 
At the end of stenting and light delivery the superficial femoral artery was ligated and 
the wound repaired. Because of the excellent collateral circulation in the lower limb of 
rabbits this does not put the leg at any risk of ischaemia. The rabbits were recovered 
and maintained on standard rabbit chow and daily aspirin (60mgs). We did not feel 
there was a need to give clopidogrel based on our previous experiments with PDT and 
angioplasty. Application of PDT with stenting in the coronary circulation may require 
its use. In the peripheral circulation its use is rare.
Animals were randomly assigned to one of three protocols.
Group 1: (n=8): stent deployed without drug or light application.
Group 2: (n=12): these animals received the ALA three hours before surgery and the 
iliac artery was illuminated to activate the drug after stent deployment.
Group 3: (n=12) these animals received the ALA three hours before surgery and the 
iliac artery was illuminated to activate the drug before stent deployment.
102
Outer
Door
x-ray screens
^ 7 7 —Assistant
Catheters
Main operating table
Anaesthetic
machine
Operator
Laser
Operating light
Inner
Door
Figure 7.1 Arrangement of Animal theatre
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Figure 7.2 Exposure of rabbit SFA during stenting and light delivery
104
Catheter aligned 
with road map Balloon expanding 
to deploy stent
Deployed 
stent ext. iliac
(A) (B) (C) (D)
Figure 7.3 Rabbit angiograms. (A) normal rabbit angiogram showing aortic bifurcation and lower limb vessels (B) road map of vessels used to position 
Catheter (C) Deployment of stent mounted on a balloon catheter (D) Deployed stent in the external iliac artery.
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Photosensitiser
The delta 5-aminolaevulinic acid (ALA) was dissolved in normal saline neutralised 
with sodium bicarbonate to pH 7. In accordance with previous pharmacokinetic 
studies, the ALA was administered intravenously at a dose of 60mg/kg body weight 
three hours before light delivery167.
Stenting and light delivery.
A unique catheter was used for endovascular illumination. The 3F monorail 20mm X 
3mm. balloon catheters had a transparent core and transparent balloon (Occam, 
Netherlands) and a blind ending channel. Light was delivered by an optical fibre with 
a 200pm core and diameter of 500pm and a distal radial light diffuser, 2 cm in length, 
marked by radio opaque markers. The entire procedure was done under image 
intensifier guidance with road mapping facility. This was invaluable in avoiding 
geometric miss. This was preloaded into the central channel of the balloon catheter. 
The catheter was introduced into the ipsi-lateral common iliac so that the balloon lay 
in the target segment just proximal to the iliac bifurcation. The catheter was delivered 
over a monorail guide-wire, which was pulled back from the balloon when the correct 
position was obtained, before illumination. During light delivery the balloon was 
inflated with air sufficiently (lOOmmHg) to occlude the blood flow but not overstretch 
the vessel. Figure 7.4 Illumination came from a Diomed 635 laser (wavelength 635nm, 
50J/cm2 at 80-100mW/cm). Figure 7.5 The total light delivery time in each procedure 
was 5-600 seconds, excluding a 60 second pause after 1 minute of light delivery. Such 
a pause during illumination has previously been shown to increase
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Figure 7.4 Light delivery in rabbit iliac artery
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Figure 7.5 Diode laser box (Diomed®)
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efficacy of a drug/light dose.150,184 After light delivery the deflated balloon, guide-wire 
and optical fibre were removed. Either before or after arterial illumination, a 15mm X 
3mm stent was loaded on a 3mm balloon catheter and introduced through the femoral 
arteriotomy and positioned under x-ray guidance, then deployed at the target site at 10 
atmosphere pressure.
Tissue harvesting and processing
All rabbits were killed by administration of an overdose of 20% phenobarbiturate. The 
abdomen was opened, the retroperitoneum exposed, and the aorta isolated and tied 
above its bifurcation. An 18F IV cannula was introduced into the distal aorta and the 
distal vessels were pressure perfused at 100mm Hg with 4% formalin for 10 minutes. 
The iliac arteries were then isolated and removed and fixed for a further 16 hours in 
4% formalin.
Four rabbits in groups 2&3 were culled at 3 days. In these rabbits the stented vessels 
were isolated, cut open along the longitudinal axis and peeled from the stent. Vessels 
from the opposite side i.e. normal un-stented rabbit artery were used for controls. The 
stent only controls had no count at day 3. The arterial tissues were embedded in 
paraffin wax, cut into 4pm sections and stained with haematoxylin and eosin (H&E). 
Microscopy images were transferred onto a personal computer via a colour camera 
(JVC TK-1281) and morphometric analysis was performed using the Lucia- M 
(version 3.52a) programme. Three sections from each vessel were examined. Each 
section was imaged and the number of VSMC nuclei per HPF (20X objective) 
counted in 8 fields in all quadrants and a mean/HPF was calculated. Table 7.1
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Cell counts per High Power Field
Vessels with light before stenting Vessels with light after stenting
0 0 0 0 91 101 123 121
0 0 0 0 107 116 128 160
4 5 5 0 138 135 152 182
12 5 9 8 175 142 154 192
13 18 13 15 201 160 163 221
20 20 35 35 207 206 191 227
57 52 57 17 233 228 218 284
35 35 25 46 293 298 246 293
Table 7.1 Circumferential VSMC/HPF in rabbit iliac at 3 days 
Vessel wall was divided into 8 segments.
Measurements were taken from each segment and averaged
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Measured values Calculated values
Rabbit
No. Group
Lumen area 
mm2
Area IEL 
mm2
Area EEL 
mm2
Intimal thickness 
mm
Intimal area 
mm2
Medial 
area mm2 %  stenosis
1 control 2.85 4.16 4.62 0.83 1.31 0.46 31.41
2 Rx 3.93 4.90 5.11 0.67 0.96 0.22 19.70
3 control 2.18 4.12 4.37 1.08 1.94 0.25 47.02
4 Rx 3.70 4.48 5.27 0.56 0.77 0.79 17.26
5 Rx 3.85 4.55 4.82 0.60 0.70 0.27 15.38
6 control 4.39 5.14 5.38 0.61 0.75 0.24 14.66
7 Rx 6.43 6.86 7.37 0.38 0.43 0.51 6.22
8 Rx 6.06 6.51 6.73 0.37 0.45 0.22 6.90
9 control 4.13 5.39 5.77 0.83 1.26 0.38 23.35
10 Rx 4.29 4.93 5.38 0.47 0.63 0.45 12.88
11 Rx 3.16 3.46 3.82 0.26 0.31 0.35 8.90
12 stent 4.14 5.77 6.23 1.12 1.64 0.46 28.38
13 control . 5.55 6.28 6.67 0.68 0.72 0.39 11.54
14 control 4.11 5.14 5.59 0.80 1.03 0.45 20.01
15 control 3.70 4.50 5.50 0.70 0.80 1.00 17.78
16 Rx 6.25 6.77 7.60 0.45 0.52 0.83 7.68
17 control 5.39 7.52 8.62 1.53 2.13 1.10 28.32
18 stent 3.64 4.29 4.79 0.46 0.65 0.50 15.22
19 stent 3.45 4.59 4.85 0.64 1.14 0.25 24.84
20 stent 3.50 4.35 4.65 0.70 0.85 0.30 19.48
21 stent 2.29 3.70 3.90 1.05 1.41 0.20 38.06
22 stent 3.33 5.42 6.00 1.61 2.09 0.58 38.60
23 stent 4.75 6.15 6.67 0.87 1.40 0.52 22.76
24 stent 3.99 6.09 6.68 0.74 2.10 0.59 34.48
Table 7.2. Morphometric measurements in rabbit iliac at 28 days
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The other rabbits (8 in each of the 3 groups) were culled at 28 days after light delivery 
and stenting. These vessels were embedded in LR White resin using standard 
techniques with the stent left in situ. Vessels were sectioned into lOp sections with the 
stents in situ on a tungsten microtome and stained subsequently with H&E.
Morphometric analysis included the following measurements: luminal area; area 
within the internal elastic lamina; the area within the external elastic lamina, and the 
intimal thickness. The intimal area was calculated by subtracting the luminal area from 
the area within the internal elastic lamina. Similarly the medial area was calculated by 
subtracting the area with the IEL from the area within the EEL. Intimal thickness was 
measured at 10 different points around the artery circumference, effectively radii from 
the vessel centre, approximately 36° apart. The mean of these 10 measurements was 
used in the subsequent analysis. Table 7.2
Statistical analysis
All values were expressed as mean ± SD. Statistical analysis was by the comparison of 
the means from each group using the unpaired Student t-test. Inter and intra-observer 
variability was assessed by reanalysis of a representative sample of histological 
sections. Area and thickness calculations were made by one observer on two separate 
occasions and by a second independent observer on one occasion. A p value of <0.05 
was considered significant.
Results
All animals survived to cull and there was no evidence of thrombosis, rupture or
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aneurysm formation in either of the PDT treatment groups or in the control group.
At 3 days after stenting and light delivery, Group 3 (PDT light before stenting), 
VSMC counts/high power field (hpf) were 17±1, while those in Group 2 (PDT light 
after stenting) were 183+17 (p< 0.006). VSMC counts/hpf in normal rabbit iliacs with 
no PDT and no stent were 222+41. Thus light treatment before stenting significantly 
reduced VSMC in the media and intima. (figure 7.6, figure 7.7 a-b) while light after 
stenting did not.
The results of artery morphometry at 28 days are summarised in table 7.3. These are 
represented in figure 7.8a-d. At 28 days the stented arteries had all developed a 
neointimal layer. In group 3 (PDT light before stent deployment) the neo-intimal layer 
was significantly thinner than that of the other two groups, (figure 7.9a-c)The 
neointimal area of group 3 was 60% less than that of group 1, but the neointima of 
group 2 rabbits was no different from that of the Group 1 (stent only) control group. 
PDT was efficacious in reducing intimal area only when the illumination was before 
stent. There was no statistical difference in either the area within the EEL or the area 
within the IEL indicating deployment of the stents to similar diameters in all treatment 
groups and no expansile remodelling in treated groups. The percent stenosis was 
calculated as a ratio of the neointimal area to the area within the IEL and was 
significantly less in Group 3 (figure 7.8e). While no immunohistological confirmation 
of endothelial integrity was possible with the LR White resin mounted tissue, a single 
layer of flat endothelium-like cells lined the stented arteries at 28days (Figure 7.9d). At 
28 days there was partial repopulation of the media in group 3 while the other 2 groups 
retained their cellularity.
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Figure 7.6 Histogram of VSMC/HPF in rabbit iliac harvested 3 days after 
PDT and stenting, (error bars represent standard deviation). There was significant 
reduction in medial cell count in the arteries where light was given before 
stenting, p values compared to light before stent group
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Figure 7.7a Rabbit iliac artery peeled from stent which was inserted 3 days 
previously with PDT illumination after stent deployment (group 2). The tissue 
was prepared for paraffin embedding and light microscopy and little medial cell 
depletion is seen.
Figure 7.7b. Rabbit iliac artery peeled from stent which was inserted 3 days 
previously with PDT illumination before stent deployment (group 3). The tissue 
was prepared for paraffin embedding and light microscopy and marked medial 
cell depletion is seen.
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Stent only controls 
(Groupl)
Light delivery after 
Stenting (Group 2)
Light delivery 
before Stenting 
(Group 3)
Area within 
EEL(mm2)
5.43±1.1 5.81±1.3 5.76±1.3
Area within 
EEL(mm2) 5.08±0.9 5.28±1.2 5.30±1.3
Luminal Area(mm2) 3.63±0.4 4.04±0.7 4.71±1.1H
Intimal Area(mm ) 1.44±0.5 1.24±0.5 0.60±0.2*
Intimal
thickness(mm) 0.90±0.4 0.88±0.3 0.47±0.1*
Medial area (mm2) 0.42±0.2 0.56±0.3 0.46±0.2
Percent stenosis(%) 28.4 24.3 11.9*
Medial Cell count at 
3 days Not done 184±17 17±1*
Medial cell count at 
28 days 167±13 155±14 56±7*
1 Statistically significant compared to Group 1
* Statistically significant compared to Group 1 and 2
Table 13  Summary of 3 day cell counts and 28 day morphometry
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(p=0.007)
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PDT before Stent PDT after Stent Stent only
Fig 7.8(a) intimal area measured in mm2 (error bars represent standard 
deviation) p values compared to light before stent group
Intimal thickness
1.5
0.5
0
(p=0.006)
(p=0.003)
PDT before Stent PDT after Stent Stent only
Figure 7.8(b) intimal thickness in mm (error bars represent standard 
deviation), p values compared to light before stent group
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Area within EEL
PDT before Stent PDT after Stent Stent only
Fig 7.8(c) area within the EEL mm2 (error bars represent standard deviation).
I
Stent only
Figure 7.8(d) luminal area in mm2 (error bars represent standard deviation), p 
value compared to stent only group
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Figure 7.8 (e) % stenosis (Ratio of intimal area to area within IEL expressed as 
a %) p values compared to light before stent group
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Figure 7.9 (a) Section of LR White resin-embedded rabbit iliac with stent in situ, 
retrieved 28 days after the procedure which involved stent deployment without 
PDT (group 1).
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Figure 7.9(b) Section of LR White resin-embedded rabbit iliac with stent in situ, 
retrieved 28 days after the procedure which involved stent deployment before 
PDT illumination (group 2).
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Figure 7.9 (c) Section of LR White resin-embedded rabbit iliac with stent in situ, 
retrieved 28 days after the procedure which involved stent deployment after PDT 
illumination (group 3).
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Figure 7.9 (d) Photomicrograph to a section from a Group 3 animal illustrating a 
contiguous layer of flattened endothelial-like cells lining the stented vessels, 28 
days after the procedure
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Discussion
This study is the first to demonstrate that endovascular PDT can be an effective 
adjuvant to arterial stenting, significantly reducing intimal hyperplasia without 
detrimental effects on the vascular integrity or thrombogenicity. However, activation 
of the photosensitiser must take place before rather than after the stent is deployed.
We used the rabbit iliac artery, a well-established model for in-stent restenosis, 
although these are disease-free, elastic arteries. There may be a difference in response 
when PDT is applied to atherosclerotic vessels with the addition of both cellular 
elements such as macrophages and fibroblasts and a lipid core. Previous studies have 
shown the in-vivo accumulation of photosensitisers in atherosclerotic plaques both in 
the cellular and non-cellular elements, although this has not been reported using 
AJLA. 185;i 86 Nevertheless? rabbit models of atherosclerosis are quite different from 
human atherosclerotic lesions and do not mimic complex human coronary disease. We 
considered that the model we used was appropriate for answering the key question of 
how PDT before and after stenting influenced cell proliferation. Our studies did only 
extend to 28 days, but this is a time point frequently used in preclinical studies. Later 
observations might have revealed a catch up of the lesion, but we think this unlikely as 
our previous studies following PDT treated arteries in rats for up to 6 months did not 
show any marked late cell proliferation.133
The striking result from this study is the observation that the media remained fully 
populated with smooth muscle cells with no inhibition of stent-induced intimal
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hyperplasia at 28 days if the light was delivered after stent deployment. There are 
several possible explanations. As the ALA was given at the same time prior to light 
delivery in both groups 2 and 3, the difference in response is unlikely to be related to 
the distribution of protoporphyrin IX (the photoactive derivative of ALA). PDT 
requires oxygen. The simplest explanation is that stent deployment stretches the 
arterial wall and makes it hypoxic. It has been documented previously in the rabbit that 
deployment of an oversize stent renders the normal arterial wall hypoxic. This effect is 
most marked in the media. Oxygenation of the endothelial layer is maintained better 
by blood flowing through the lumen of the vessel.187 This may explain why endothelial 
loss was seen in arteries illuminated after stent insertion, although this loss may be at 
least partially attributable to the trauma of the balloon-mounted stent delivery. By 28 
days all stented arteries had a layer of endothelial-like cells coating the lumen surface 
of the artery. Several studies report complete and even accelerated regrowth of normal 
vascular endothelium after PDT without stenting, with no evidence of thrombosis or 
any other impairment of blood flow.162 188'190 Early re-growth of endothelium after 
PDT may play a role in the inhibition of VSMC proliferation and intimal hyperplasia 
and may also play a role in reducing thrombogenic complications after stent 
placement.
There are other possible explanations for our results. The vascular stent is a metal tube 
mesh, so optical shadowing from light delivered from within the lumen of the stent 
must occur to some degree. However, the wire of the stent struts is so thin compared to 
the penetration depth in tissue of the red light used (typically about 2mm) that
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scattering of light within the tissue should make this a minor consideration. 
Nevertheless, a recent report describes inhibition of intimal hyperplasia from PDT 
given after stenting of the femoral artery, but employing illumination of the external 
surface of the artery, thus avoiding strut shadowing.191 Another possibility is that the 
mechanical stretching of the arterial wall by the stent could lead to on-going 
stimulation of VSMC proliferation (in contrast to the single insult of a balloon 
angioplasty followed by removal of the balloon). However, this is less likely as the 
effect would have been expected to be the same in both PDT treated groups.
Several studies report complete and indeed accelerated re-growth of endothelium after 
PDT.162’188'190 The complexity of the procedure and the tissue retrieval meant that we 
did not define the specific effects on the endothelium of PDT with stenting, since 
endothelium-specific staining was not possible in the LR White resin embedded tissue. 
Procedure-related physical disruption of the endothelium would be predicted, but since 
the stent was stripped from the artery at 3 days prior to processing for histology, 
further damage occurs. Nevertheless, we saw an intact endothelium-like layer of cells 
when the iliac arteries of all groups were examined 28 days after injury. There were no 
thrombotic complications despite only aspirin prophylaxis. Poor endothelial re-growth 
with brachytherapy and drug eluting stents has necessitated long term anti-thrombotic 
treatment with associated expense and risk of bleeding complications.119,192,193 The 
suggestion of rapid re-endothelialisation after PDT is particularly appealing to the 
clinical practitioner as it means that adjuvant PDT may have a particular place in the 
treatment of diffuse coronary artery disease and long lesions.
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In general, the response of tissue to PDT is complex, with inflammation and 
microvascular damage, but in the arterial wall the development of medial apoptotic 
bodies, TUNEL staining of residual nuclei and the lack of an early inflammatory 
infiltrate suggest that the predominant effect is apoptosis.194-196 It inhibits VSMC 
proliferation and migration, increases cross-linking in collagen and extra-cellular 
matrix and promotes positive remodelling of the artery. The prevention of intimal 
hyperplasia and restenosis seen in this study is linked closely to ablation of cells in the 
media. The key role of medial vascular smooth muscle cells in the intimal response to 
a stent is reflected in the significant reduction in neointimal area and thickness only 
when the PDT has caused depletion of the cellular elements of the wall i.e. when light 
delivery was before stent deployment. A correlation between cell depletion/ablation 
and efficiency is seen also with other techniques now used to prevent or treat in-stent
1Q7* 1Q8 _restenosis, such as drug-eluting stents or brachytherapy. ’ The partial medial cell 
repopulation at 28 days documented here is consistent with repopulation of the media 
of pig coronaries illuminated endovascularly172, although cell depletion may persist for 
six months or more in rat carotid arteries133.
How does PDT produce these effects? In a series of experiments Heckenkamp et al 
looked at the effect of y-radiation and PDT on a number of SMC and functions of the 
extra-cellular matrix (ECM).199 When cultured in 100% calf serum (CS) PDT 
completely inhibited cellular proliferation compared to controls. In the y-radiated 
group there was significant decrease in proliferation but less than the PDT group. 
Mitochondrial metabolic activity in the VSMC doubled in control groups when
stimulated with CS compared to no activity being detected in the PDT group. In the 
y-radiated group there was no difference in activity compared to controls. VSMC, 
grown in media containing mechanically injured VSMC responsible for injury- 
associated growth factors, showed a significant increase in mitogenesis. PDT inhibited 
this increase while no effect was seen with y-radiation. Perhaps most importantly 
apoptotic cell death was found to be the major cytotoxic mechanism causing cell death 
following PDT while no significant apoptosis was seen after y-radiation.196 This was 
confirmed by TUNEL Stain, DNA fragmentation ladders, and with characteristic 
changes seen on Electron microscopy. Work from the same centre had also shown that 
migration of VSMC in PDT treated ECM is significantly inhibited.132,200 It is 
suggested that PDT causes release of lysosomal enzymes which activate Caspases 
such as Caspase 9.196 Alternately they could damage mitochondria stimulating the 
release of cytochrome C again activating the caspase cascade.201 As already explained 
all the effects of PDT are probably mediated through singlet oxygen species. Since the 
half-life of these species is extremely small the effects of PDT are well localised by the 
distribution of drug and illumination of light. What is perhaps most important is that it 
does not stimulate an inflammatory reaction with no evidence of phagocytes seen in 
the areas illuminated. The debris is eliminated by either redistribution in the media or 
by being washed away by the blood.
One of the key attractions of PDT is the nature of the biological effect. Despite its 
increasing use in a range of specialities, there is no evidence of cumulative toxicity and 
it has often been used to treat the same site several times. The photon energy of the
red light used is too low to damage DNA. There is a lack of any effect on the 
mechanical integrity of arteries or on the blood flow through them and a lack of any 
chronic changes detectable histologically.167,172 This body of evidence makes PDT an 
attractive option as a possible alternative to drug eluting stents and brachytherapy. 
However, as PDT only works if the light is given prior to rather than after stent 
deployment, it may not be of value for the treatment, rather than prophylaxis, of in­
stent restenosis. The published data on stent induced hypoxia in the wall of arteries 
showed that there was some improvement in the hypoxia when the stents had been in 
situ for several weeks, but further experiments would be required to see if PDT has
187any potential for treating rather than preventmg in-stent restenosis.
Remodelling with vessel shrinkage is a major contributor to restenosis after balloon 
angioplasty. Previous studies from our group and others have shown that following 
angioplasty with adjuvant endovascular PDT but without stenting, there is inhibition of 
constrictive remodelling.172;202 Remodelling is less important in the presence of a stent, 
but it is reassuring that we saw no evidence of aneurysmal dilatation following PDT, 
nor signs to suggest stent mal-apposition, which has been a feature of both 
brachytherapy and drug eluting stents.197;198;203 Further, no signs of injury to adjacent 
tissue have been reported with ALA-PDT, which may reflect the limited tissue 
penetration (2mm) of the 635nm light used to activate protoporphyrin IX, the active 
metabolite of ALA. The impaired endothelial re-growth after brachytherapy and drug 
eluting stents has necessitated long term anti-thrombotic treatment with the associated 
expense and risk of bleeding complications.109;119;2()4;205 The rapid re-endothelialisation
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reported after PDT in animals allows us to speculate that in the clinical setting 
adjuvant PDT may require less subsequent maintenance drug therapy. The 
endothelium may not heal so well in atherosclerotic human vessels as it does in non- 
atherosclerotic animal arteries, but the one clinical study so far reported with extended 
follow up of 4 years, did not describe any evidence of late thrombotic complications 
despite only aspirin prophylaxis.206 A recent report on long term follow up of drug 
eluting stents described 4 cases in which drug eluting stents in coronary arteries 
thrombosed more than a year after insertion, when anti-thrombotic therapy was 
reduced.207 Two of these patients also had non drug eluting stents, which did not 
thrombose. There were no thrombotic complications in our experiments. On the 
evidence currently available from this and other studies, arteries tolerate PDT 
remarkably well, in the short and long term, although the clinical data available is very 
limited. No reports of arterial PDT have described any evidence of the chronic 
changes known to be associated with ionising radiatioa
Several other drugs have been used to photosensitise arteries in studies of the effect of 
PDT on atherosclerosis and restenosis. Chloroaluminum sulfonated phthalocyanines 
(CAsP) PDT is effective in inducing apoptotic cell loss and inhibiting intimal 
hyperplasia after angioplasty-like injury. However, only external illumination of an 
exposed artery with optical shielding of adjacent tissue has been described due to the 
high tissue penetration of the activating light of 675nm wavelength. This would 
limit its endovascular application. The photosensitiser Motexafin lutetium is activated 
by far-red light of wavelength 732nm, which is not attenuated by the presence of
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blood, so an optical fibre without a blood flow-excluding balloon catheter can be used. 
Motexafin Lutetium is reported to accumulate preferentially in macrophage rich areas 
of plaques induced by injury and cholesterol feeding and upon light activation these 
cells are ablated, raising the potential of plaque specificity208’209. Another sensitiser, 
NPe6, has the specific advantage of rapid uptake into injured and atherosclerotic 
arteries, that may allow illumination to follow immediately after local or systemic drug 
administration.131
ALA was administered systemicaily and might be expected to cause generalised 
photosensitivity. However, a pilot study of ALA PDT as an adjunct to femoral 
angioplasty along with other clinical studies on PDT treatment of cancer and 
dysplastic lesions have confirmed encouraging results in terms of tolerability.141,161 
Indeed, as PDT has no long term sequelae in terms of DNA damage and healing, it 
may be possible, as with other disease applications, to use vascular PDT repeatedly as 
many times as necessary. Motexafin lutium has also been tested in clinical trials of 
peripheral and coronary vascular disease.166,209
In practical terms, PDT is more complex than inserting a drug eluting stent, but with 
the specifically modified balloon catheter described here, it is straightforward to 
deliver the light endoluminally. The need to administer ALA several hours prior to 
angioplasty and to take simple precautions against exposure to bright ambient light for 
1-2 days are relatively minor inconveniences.183 The equipment required for PDT is 
certainly simpler than the facilities required for safe delivery of the ionising radiation 
needed for brachytherapy.
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On the limited evidence available to date, it would appear that PDT may be able to 
reduce the incidence of re-stenosis after angioplasty, with or without stenting, with 
few, if any, long term adverse effects on the arterial wall. This study demonstrates, for 
the first time, that PDT is an effective adjuvant to arterial stenting, significantly 
reducing intimal hyperplasia, without detrimental effects on vascular integrity and 
healing when light is delivered prior to stent deployment.
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Chapter 8. Clinical pilot study
Introduction
Percutaneous transluminal angioplasty is well established in the treatment of occlusive 
and stenotic atheromatous disease of the coronary and peripheral arteries. It is 
associated with an excellent procedural outcome but is limited by the development of 
restenosis. In clinical practice, pharmaceutical approaches for preventing this have 
been disappointing. Stenting has led to a modest reduction in restenosis rates in 
coronary and iliac angioplasty but has failed to have a major benefit in femoral- 
popliteal disease. The efficacy of brachytherapy in the treatment and prevention of in­
stent and post angioplasty restenosis is recognised. However, there remain concerns 
about radiation therapy because of reports of late thrombotic occlusion, and the long­
term safety of ionising radiation remains unclear. Another promising option is the use 
of stents, which elute a cytostatic drug such as sirolimus or paclitaxel. The results with 
drug-coated stents are excellent.
As described in the previous chapters photodynamic therapy involves the activation of 
a systemicaily administered photosensitising agent by the application of non-thermal, 
non-ionising radiation, usually in the form of low power red light from a laser. In both 
small and large animal models of balloon injury to normal arteries, these histological 
changes are associated with a decrease in intimal hyperplasia. There is also inhibition 
of negative remodelling.
In 1999 we reported the short term results of a pilot clinical study of adjuvant
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photodynamic therapy, in a total of 8 lesions in 7 patients undergoing repeat
w
superficial femoral angioplasty for restenosis. At six months follow up all patients 
were asymptomatic, there were no arterial complications and there was no evidence of 
restenosis. The aim of the present study was to document in detail the long-term 
outcome in this group of patients.
Materials and Methods
All patients gave informed consent to the study, which was approved by the Ethical 
Committee of The University College London Hospital NHSTrust. In the original 
study, 7 patients (age range 59-86 years), who had developed symptomatic restenosis 
of the superficial femoral artery within six months of angioplasty (one with 2 lesions 
in the same artery) were enrolled. All of these lesions were >4cms as this was the size 
of the balloon. Table 8.1 Three had occlusions of the SFA and the other lesions were 
severe restenosis (>70%). Risk factors included hypertension (three), diabetes mellitus 
(two) and continuing cigarette smoking (three). Patients received 60mg/Kg of the 
sensitising agent 5-aminolaevulinic acid (ALA) by mouth, which is converted in-vivo 
to its photoactive metabolite protoporphyrin IX. Four to six hours later they underwent 
superficial femoral angioplasty of the re-stenosed or occluded site, using a 4cm length 
balloon of appropriate diameter, all treatments resulting in a residual stenosis of less 
than 30%. All patients received 5000U of intravenous heparin before the angioplasty. 
The angioplasty was immediately followed by the delivery of light (50J/cm2 at a 
wavelength of 635nm from a copper vapour pumped dye laser) to the dilated site via 
an optical fibre with a 4cm terminal diffuser within the transparent angioplasty
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Patient Age Sex Risk factorsf Smoker PTA Balloon Diameter (mm)
1 59 M None Ex 7
2a&b* 70 F H Ex 4
3 73 M CH Ex 4
4 64 M HD Current 6
5 84 M CD Current 5
6 86 F H Non 5
7 66 M CH Current 6
t  H- Hypertensive, C- Coronary Heart disease, D- Diabetic 
* Patient 2 received PDT to two separate lesions in the same leg (2a and 2b)
Table 8.1 Patient demographics in pilot study
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balloon. All patients were subsequently treated with long-term aspirin (75-150mg). 
Follow up was by Duplex scanning of the treatment site and peak systolic velocity 
ratio (PSVR) at 1, 3 and 6 months and intravenous digital subtraction angiography at 
six months. As stated above, all treated sites were patent at 6 months.
The long-term safety and efficacy were assessed by clinical review and repeat arterial 
imaging. The presence or absence of intermittent claudication, ischaemic rest pain and 
ulceration was established and all patients were offered repeat Duplex imaging of the 
treatment site by an experienced ultrasonographer. The original lesion site was 
identified by its distance from the medial femoral condoyle, recorded at the time of the 
original PDT procedure. Doppler velocities were measured immediately proximal to 
the lesion and within the lesion site to determine the peak systolic velocity ratio. In 
accordance with the original study protocol, a PSVR greater than 2.0 was defined as 
indicating restenosis.
Results
All seven patients were followed up for a total period of 42-51 months (mean 48 
months) after PDT. Table 8.2 No patient had developed critical limb ischaemia or 
ulceration during the follow up period. There were no arterial complications at the 
treatment sites in any of the subjects examined at any time during follow up. The 
results of the PSVR measurement are represented in Figure 8.1 Only one patient 
(patient 3) had symptoms from recurrent disease at the site treated with adjuvant PDT.
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Patient Long term follow up (months) PSVR
Symptoms at long term 
follow up
Pre-PDT longterm
1 51 4.5 2.0 None
2a 51 3.7 Declined None
2b - 5.5 -
3 51 Occluded 3.7 Mild Claudication
46 Occluded 0.9 None
5 47 4.7 1.0 None
6 47 8.7 1.9 None
7 42 Occluded 1.2 None
* Patient 2 received PDT to two separate lesions in the same leg (2a and 2b) and 
underwent repeat angioplasty of a new lesion proximal to these after 12 months
** Patient 4 underwent angioplasty and brachytherapy to the contra-lateral 
femoral artery 2 years after PDT to right femoral artery
Table 8.2 Results of peak systolic velocity ratio (PSVR) data derived 
from duplex scanning during the pilot study and at long term follow up
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PS
VR
Patient 1
Patient 2 Lesion 1 
Patient 2 Lesion 2 
Patient 3 
Patient 4 
Patient 5 
Patient 6 
Patient 7
i  r
Pre Post 1
Follow-up (months)
Figure 8.1 Individual case data showing PSVR during study period
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He had had 2 previous occlusions at this site (at his first presentation and when he was 
re-treated with adjuvant PDT). He developed mild claudication 18 months after PDT 
which, unlike his symptoms prior to PDT, was not limiting and which has been stable 
for the last 2 years. The most recent Duplex and Doppler ultrasound scanning (51 
months after PDT) showed evidence of restenosis (PSVR=3.7) with smooth plaque at 
the treatment site.
The other six patients were asymptomatic at their most recent review. Patient 2 had 
experienced a recurrence of claudication one year after angioplasty with adjuvant PDT 
and subsequently underwent repeat angioplasty to two new lesions proximal to one of 
the two sites in the same artery treated originally. The angiogram at that time showed 
no evidence of restenosis at either of the PDT-treated sites. (Figure 8.2). This patient 
remained asymptomatic thereafter as far as her leg was concerned, but declined a 
further Duplex study as she had had a stroke and was very frail.
Patient 4 had developed symptoms relating to new disease in the contra-lateral leg. 
This was treated with angioplasty and brachytherapy 26 months after the PDT 
procedure. He has since developed mild claudication in that limb, but has no 
symptoms in the PDT treated leg. The bilateral angiogram at the time of
brachytherapy showed no evidence of restenosis at the site originally treated with 
adjuvant PDT and the duplex scan 46 months after PDT showed a PSVR of 0.9. None 
of the 5 currently asymptomatic patients who agreed to undergo a repeat Duplex 
examination (including two who had occluded vessels at initial enrolment) 
demonstrated any evidence of significant restenosis (Table 8.2).
a b e d
Figure 8.2 Right femoral angiograms from patient 2 illustrating
(a) Two tight irregular stenoses as indicated (arrows) at original angiography
(b) The arteries after angioplasty with adjuvant PDT of these two lesions in series (arrows)
(c) IV DSA at 6 months showing no restenosis at the treated site (arrows) with suggestion of new lesion proximal to the treated site (arrowhead)
(d) Further angiogram 1 year later showing new lesions (arrowheads) proximal to the previous lesions. There is a moderate degree of concentric 
narrowing at the site of previous angioplasty with adjuvant PDT (arrows), but the distal vessel is unobstructed (arrow).
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Discussion
In this small study, only one of 8 lesions treated by angioplasty with adjuvant PDT 
developed symptomatic restenosis at the treated site (PSVR 3.7) during the follow up 
period of nearly 4 years and these symptoms were considerably milder than those prior 
to PDT. Two others came close to the definition of restenosis (PSVR over 2.0) with 
PSVR values of 1.9 and 2.0, but both remained asymptomatic. There were no re­
occlusions. Recurrent symptoms in one other patient were due to a new lesion, 
separate from those treated previously in the same leg. The numbers are small, but 
these results are most encouraging.
The long-term outlook following angioplasty for femoral and popliteal disease is 
unsatisfactory with more than most of the failures due to occlusion or restenosis at the 
treated site. The other symptomatic failures were related to disease progression, as was 
seen in our patient 2. Our group of patients, with focal disease and good run-off, 
belong to the group of patients with femoral-popliteal disease who have the most
9 1 0 9 1  1favourable outcome after angioplasty. ’ However, all had restenosis or occlusion 
after a previous angioplasty and would have been anticipated to have a poor outcome 
from further intervention.
The most important and reassuring observation from this extended follow up is the 
finding that there was no evidence of localised arterial complications such as dilatation 
or aneurysm formation in those scanned or undergoing repeat angiography at a mean
of 4 years after treatment with adjunctive PDT. Further, there was no evidence of sub­
acute thrombosis or occlusion.
The numbers in this study are small and the data is uncontrolled and there is therefore 
a need for a randomised controlled trial of femoral balloon angioplasty with and 
without adjuvant photodynamic therapy to determine the clinical value of this therapy.. 
Adjunctive PDT may provide us with a new strategy to prevent restenosis after 
angioplasty for occlusive and stenotic vascular disease. In the next chapter we report 
the results of our randomised controlled trial.
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Chapter 9. Randomised Controlled Trial
Introduction
Evidence from in-vitro work and in small and large animals would suggest that PDT is 
efficacious in reducing the incidence of restenosis after balloon injury in an artery. 
(Chapters 5 6 and 7) Pilot studies have also established that with the right combination 
of drug and light dose and optimum drug light interval the procedure can be applied in 
a clinical scenario safely and efficiently. They also show lack of significant stenosis at 
4 years. (Chapter 8). The work described below is the first randomised controlled trial 
comparing standard angioplasty with angioplasty with adjuvant PDT.
Justification of methodology
A randomised controlled study using 5-ALA PDT as an adjuvant to angioplasty was 
deemed to be the best method of proving its efficacy for a number of reasons. Firstly 
the depth of effects with red light induced PpDC excitation limits extra arterial tissue 
damage compared to other photosensitisers. Secondly the limited skin photosensitivity 
period of PpIX makes it ideal for use in a non-malignant condition with short hospital 
stay. This would allow photosensitisation on the day of the procedure with angioplasty 
a few hours later, a overnight stay in the hospital and discharge the next day much in 
line with normal practice for patients undergoing PTA alone
Thirdly the safety of 5-ALA has been shown in both animal and pilot clinical studies. 
An oral dose of 60mg/kg was selected as this had been safely used in the pilot study. 
As in the pilot study, it was given in 3 divided doses to give a longer plateau and
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avoid a post bolus peak. In human studies in patients undergoing operation for 
gastrointestinal and colorectal malignancies there is a peak PP9 fluorescence activity at 
4-6 hours after oral administration.212 Six hours was used in the pilot study with good 
results and was hence used in my controlled study as well.
Fourthly the clinical pilot study had shown no stenosis at the treated site in 8 lesions at 
4 years. The established way of proving the efficacy of a particular form of treatment 
is in a randomised controlled double blinded study. Hence our study was designed in 
this manner.
Methods 
Patient selection
Full approval from the Ethical Committee of the Royal Free and University College 
London Hospitals NHS Trust was obtained for the study. Our hypothesis was that we 
could reduce the rate of restenosis following PTA of the SFA by a significant level by 
using adjuvant ALA-PDT with PTA. All patients with symptomatic SFA lesions i.e. 
stenosis or occlusions were offered entry in to the trial and were randomised into 2 
arms, one receiving standard PTA and the other group receiving PTA with adjuvant 
ALA-PDT. We anticipated a restenotic rate of ~ 50% in patients undergoing routine 
PTA and a reduction of restenotic rate to 25% in patients under going PTA with 
adjuvant ALA-PDT. In consultation with a statistician in order to achieve a power of 
80% to show a statistically significant difference between the 2 groups (p<0.05) we 
would need to recruit 66 patients in each arm, i.e. a total of 132 patients.
All patients were consented following a full explanation of the trial backed up by a 
written information sheet. Angioplasty limited to the SFA segment was elected due to 
the relatively poor current outcome for PTA in this segment and the ease with which 
any salvage bypass surgery could be carried out in the event of an unexpected 
complication.
Although in the pilot study only patients who had experienced restenosis following 
previous angioplasty were selected in the RCT we used patients presenting for both 
primary and redo angioplasty. This was because we had established the safety of the 
procedure in the pilot study. Including patients for primary angioplasty allowed us to 
recruit larger numbers of patients.
All patients were recruited prospectively. They were excluded if they had pre-existing 
liver disease (as ALA can cause elevations of liver enzymes). All patients presenting 
with technically suitable symptomatic lesions of the SFA were recruited into the trial. 
The presenting symptoms included claudication, rest pain, non-healing ischaemic 
ulcers or ischaemic gangrene of the foot. Following a complete history and 
examination all patients had a duplex scan of the arteries of the leg. If the duplex scan 
confirmed a lesion in the SFA suitable for standard PTA the patient was included in 
the trial. These included stenosis and short occlusions (< 4 cm) of the SFA. Long 
occlusions, which were not suitable for standard angioplasty, were not included. The 
degree of stenosis was derived using peak systolic velocity ratio. This is the ratio of 
velocity of blood flow in the narrowed segment in the velocity of blood flow to the 
closest normal part of the vessel. A ratio of greater than 2 implies a significant
stenosis of > 50% All patients were started on aspirin and were put on lipid lowering 
drugs if required. Smoking cessation was advised but was not always complied with. 
Any pre-existing diabetes mellitus (DM), hypertension (HT) or ischeamic heart 
disease (IHD) was recorded and its management optimised.
Drug delivery
Patients were then randomised in the 2 amis. The randomisation was done by the 
pharmacist dispensing the ALA by selection of a pre-labelled envelope. The patients in 
the treatment arm were given 5- ALA (DUSA Pharmaceuticals. Inc., Tarrytown NY) 
in the dose of 60mg/kg. This was given in 3 divided doses of 20mg/kg. The first dose 
was given 5 hours before the procedure and at hourly intervals thereafter. The ALA 
was dissolved in orange juice and drunk by the patients. The control patients were 
given sugar dissolved in orange juice. All patients both in the treatment and control 
arm were housed in subdued light from the time of ingestion of the drug for 24 hours. 
The patient was blinded as to which arm he or she was in. The primary investigator 
was also blinded. The drug was delivered by the pharmacist, who along with the laser 
physicist and the radiologist were the only people who were un-blinded.
Procedure and Light delivery
All patients were given prophylactic analgesia (diclofenac PR or IM) before the 
procedure. Patients were starved for 6 hours before the procedure apart from the 
orange juice used to dissolve the ALA or placebo. An angiogram was done before the 
angioplasty to confirm the suitability of the lesion. If the lesion was found to be 
unsuitable no light was delivered. If angioplasty was done 5000 IU of heparin
was given intra-arterially. The procedure was done through a femoral approach under 
local anaesthesia and sedation if required. A standard Seldinger technique was used. 
After needle puncture of the common femoral artery a guide-wire was introduced and 
a sheath was introduced over the guide wire. After doing the angiogram the balloon 
was introduced over the guide-wire and aligned with the lesion to be treated. A special 
balloon, the Powerflex 3 (Cordis Ltd), with a transparent core allowing light diffusion 
was used. Figure 9.1 All balloons were 4 cm in length with the diameter ranging from 
4-7 mm. The balloon was inflated, maintained for 15-30 seconds and deflated again. In 
patients in the treatment group the guide wire was replaced by an optical fibre with a 
400-pm core (Pioneer Optics) with a 4-cm diffuser. Figure 9.2 
The tip of the fibre was marked with a radio-opaque marker visible on an image 
intensifier. The diffuser was aligned with the balloon and the balloon re inflated at low 
pressure to occlude blood flow. Figure 9.3 Light was provided by a 635-nm diode 
laser (Diomed). Light was given at 50 J/cm2 with the fluance kept below 120 mW/cm 
to avoid any thermal injury. There was a one-minute dark interval after 20% of the 
light delivery in order to allow re-oxygenation of the arterial wall. Light delivery took 
8 minutes including the window. A check angiogram was done at the end of the 
procedure. Figure 9.4 is an example of a successful treatment in the treatment group. 
The patients were kept on a flat bed for 4-6 hours after the procedure and in subdued 
lighting overnight. All patients who underwent all of these procedures were deemed to 
have completed the protocol. Even though some patients did not have the full dose of 
light they were included in the analysis and were deemed to have completed the 
protocol.
Figure 9.1 Custom made PTA balloon for RCT. It has a transparent central 
channel to allow light transmission
Figure 9.2 Custom made 400 pm core Optical light delivery fibre for RCT
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Figure 9.3 Light delivery fibre in angioplasty balloon. The balloon is inflated 
to occlude blood flow and light is delivered at 635nm.
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a b c d
Figure 9.4 Right femoral angiograms illustrating (a) occlusion o f the femoral artery before angioplasty and photodynamic therapy (b) guide wire 
successfully across the occlusion (c) angiographic appearance after angioplasty and adjunctive PDT and (d) repeat angiogram o f the right 
femoral artery 6 months later demonstrating patency and no evidence o f restenosis
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Monitoring
All patients had their pulse and blood pressure monitored along with temperature and 
respiration on an hourly basis on the day of the procedure. All patients had a foil blood 
count with renal and liver function tests done prior to the angioplasty. The liver 
function tests were repeated on the day following the angioplasty. The patients had a 
duplex scan on the day before for confirmation of the lesion, measurement of the ankle 
brachial pressure index (ABPI) and measurement of the degree of stenosis. The 
efficacy of the angioplasty was recorded by another duplex scan on the day following 
the angioplasty for re-measurement of the treated site and measurement of the ABPI. 
In the absence of any complications the patients were discharged following the second 
scan. The patients were recalled at 1, 3 and 6 months after the procedure for follow-up 
scans. Patients who showed evidence of restenosis on duplex were re-assessed 
clinically and if necessary had an angiogram with radiological or surgical intervention. 
The trial was not run on an intention-to treat basis. This was so that we could analyse 
the restenosis rate directly attributable to the ALA-PDT. However I have presented my 
results taking into consideration all patients in the trial as well as looking at those 
patients who have completed the protocol.
Results
In the 2 years I co-ordinated the trial, 66 patients were recruited. Only half the 
anticipated number of patients was recruited. Their demographics are summarised in 
table 9.1. Of the 33 patients in each arm 26 in the treatment arm and 28 in the control 
arm completed the protocol. Of the 8 patients in the treatment arm that did not 
complete the protocol, 5 were found to be unsuitable at angiogram, 1 was
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Treatment group Control group
Total patients 33 33
Age 68 72
Male: female ratio 1.2:1 1:1.1
Risk factors: (%)
Ischaemic heart disease 12 (36) 8(24)
Diabetes 7(20) 10 (32)
Hypertension 24 (72) 20 (61)
Previous stroke 8(24) 5(14)
Renal disease 4(12) 5(14)
Previous arterial surgery 9(28) 6(18)
Previous PTA 14 (40) 9(28)
Smoker: (%)
Present 10 (32) 10 (32)
Ex 18 (55) 18 (55)
Symptoms
Claudication alone 17 (52) 18(55)
Rest pain 8(24) 8(24)
Tissue loss 8(24) 7(21)
Table 9.1 Patient demographics in RCT
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withdrawn because of cardiac instability just before the procedure and in 1 patient the 
lesion could not be crossed by a guide-wire for angioplasty. 1 was lost to follow-up. In 
the placebo group, of the 5 patients who did not complete the protocol 4 lesions were 
found to be unsuitable at the angiogram and 1 could not be negotiated with a guide- 
wire. Light delivery was cut short in 3 patients in the treatment arm because of pain 
during light delivery. One of them received 90% of the light dose one received 60% 
and one 40%. As mentioned in the methods these patients were deemed to have 
completed the protocol and analysed as part of the treatment arm. This has been 
summarised in the CONSORT flow diagram213 Fig 9.5.
Table 9.2 and 9.3 summarise the findings at follow-up at 3 and 6 months. Briefly of 
the 25 patients in the treatment group who completed the protocol 3 occluded 
immediate post-procedure and 5 more developed restenosis at 6 months. In the control 
group of the 28 patients who completed the protocol 1 occluded immediate post­
procedure and 12 more developed restenosis at 6 months. There is no statistical 
difference between these outcomes. The PSVR was lower and the ABPI was higher in 
the treatment group at 6 months but again there was no statistical difference.
The complications recorded are summarised in the table 9.4. A fall of greater than 
20mm Hg in the mean pressure or a systolic blood pressure of > 100mm Hg was 
considered a significant drop in blood pressure. 6 patients in the treatment group 
recorded a significant drop in blood pressure while only 2 in the control showed 
this. (p<0.05 Fisher exact test) On the recommendation of the risk assessment reviewer 
a safety review was carried out after 30 patients during which the hypotension
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Figure 9.5 CONSORT statement for RAAPT trial
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Treatment group Control Group
Number randomised 33 33
Successful PTA ± PDT 26 28
Lost to follow up 1 0
Acute Post procedure 
thrombosis 3 1
Patent vessels at day 1 23 27
Patent vessels at 3 months 20 19
Patent vessels at 6 months 18 15
Table 9.2 Summary of Follow-up -1
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Treatment group Control Group
PSVR: median (range)
Pre procedure 2.2 (0-4.6) 2.9 (0-7.8)
Post-procedure 1.32 (0-2.7) 1.58 (0-9.5)
3 months 1.35 (0-3.3) 1.51 (0-3.8)
6 months 1.54 (0-3.4) 1.7 (0-3.6)
ABPI: median (range)
Pre procedure 0.7 (0.2-1) 0.7 (0.4-1)
Post-procedure 0.87 (0.4-1) 0.9 (0.4-1)
3 months 0.9 (0.5-1) 0.89 (0.5-1)
6 months 0.91 (0.6-1) 0.88 (0.5-1)
Table 9.3 PSVR and ABPI in patients who had successful PTA ± PDT. N=26 in 
the treatment group and 28 in the control group. One patient was lost to follow- 
up in the treatment group at 3 and 6 months.
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Treatment arm Control arm
Pain during procedure 4 0
Significant hypotension 6* 2
Haematomas 0 2
Post procedure 
thrombosis 3 1
Table 9.2 Recorded complications in RCT
* p = 0.03 (Fisher exact test) compared to control arm
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caused by ALA was investigated further and found to be potentiated by Anti­
hypertensives and diuretics. The protocol was changed so that the last dose of these 
drugs was omitted before the procedure and the patients were pre-filled with a litre of 
crystalloid No hypotension was recorded after these changes. There were no instances 
of fluid overload.
Of the 2 patients in the control group who developed haematomas at the puncture site 
one had to be explored for a repair of pseudo-aneurysm.
The raw data of PSVR and ABPI in all patients completing the protocol is documented 
in tables 9.5 and 9.6 at the end of the chapter.
Discussion
This is the first clinical trial comparing Standard PTA with PTA with adjuvant PDT. 
An initial pilot study of PTA with adjuvant PDT conducted in our department had 
shown only one site of partial restenosis at the treated site at 4 years in 8 lesions. It had 
also shown the treatment to be safe and clinically feasible. A randomised controlled 
double blinded trial was essential to prove the efficacy of ALA PDT in preventing 
restenosis.
The trial highlights a number of problems which are encountered while running a 
randomised trial of this nature. The first striking problem is the number of patients 
recruited into the trial. While the initial intension was to recruit 132 patients into the 
trial I could recruit only 66 in the 2 years I co-ordinated it. During the planning of the 
trial it was indeed anticipated that we would be able to recruit the required
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number (132) into the trial within this 2 year period. The funding for the trial which 
was provided for by industry was for 2 years. There a number of reasons I could not 
recruit. To begin with although all the personnel and ethics approval was in place there 
was a delay in the procurement of the necessary equipment by 2-3 months. Every 
patient which was thought to be suitable on the duplex was offered entry in to the trial 
and every patient who was offered the trial agreed to participate in the trial. Hence 
there just were not enough patients presenting to us who were suitable for the trial. Part 
of the reason there was a discrepancy between the anticipated number was that only a 
percentage of SFA lesions were suitable for entry into the trial i.e. only those with 
lesions smaller than 4 cms. SFA angioplasty is certainly extended to lesions far longer 
than these. Moreover of the patients who were initially thought to be suitable for the 
trial, 20 % did not complete the protocol. This was because of a variety of reasons but 
the most common was because the lesions were found unsuitable on angiogram. 
About 6-8 months into the trial we realised that we were not going to get enough 
patients from a single centre i.e. UCL and Middlesex hospital. Hence we got ethics 
approval and stared recruiting from a second centre i.e. Royal Free Hospital and after a 
few more months from the Chelsea and Westminster hospital. In spite of this we were 
not close to getting the required numbers. Expansion to any more centres would deem 
the trial a multi-centre trial which come its own added set of problems. Multi-centre 
trials need special Ethics Committee permission requiring a central ethics committee 
with resubmission of the proposal as opposed just needing Chairman’s actions at the 
Royal Free and Chelsea and Westminster Ethics Committees. Specifically for this trial 
it would have been a logistical problem in terms of equipment and personnel. Since
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we had only 2 diode laser machines and only one laser physicist a multi-centre trial 
would have been impossible with the current arrangement. The special catheters we 
were using for the trial would have either to be ordered by the procurement department 
of the respective hospitals or provide for by us, raising the issue of funding for these 
catheters as well approval of use of this non-standard equipment at these hospitals. The 
use of lasers would also require approval of the health and safety departments with the 
satisfaction of their rules. The smooth conduct of this procedure with ALA 
administration and light delivery at the appropriate time would involve the cooperation 
of a number of different departments and skilled personnel and equipment at the same 
time and place. Finally at the end of 2 years we had no more handing for the trial and 
hence we suspended the trial.
The second problem is one of co-ordination of all the personnel involved in the 
administration of the treatment. As already mentioned the smooth running of the trial 
needed a radiologist, vascular surgeons, specialised nurses and wards (given the 
patients needed to avoid sunlight in peri-procedural period), laser physicist, 
pharmacist, vascular technologist, the nurse co-ordinator and myself. We feel lucky in 
obtaining co-operation from all these people sometimes at short notice in running the 
trial. Anyone working in NHS hospital will realise the difficulty in getting beds, but 
we seem to have managed to not only get a bed when we wanted but one where it 
would be possible to shield the patient from sunlight.
The third problem is one of non-suitablity of potential patients at the time of their 
angiogram. As we have shown we lost about 20% of our patients mainly because
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the lesion was found to be unsuitable on angiogram. This is due to both over and under 
estimation of the lesions on Duplex. This is bound to happen in any trial involving 
angioplasty and hence should be taken into account when estimating numbers. This 
was however accounted for when the number need to treat were calculated. In fact if 
all patients recruited were suitable we would need only 45 in each arm to achieve 
statistical significance at 0.05 level with a power of 80% with at least a 25% difference 
in stenosis rates in the 2 groups.
Finally one has to take into account the statistics involved in drawing any conclusions 
from this trial. The patients were unblinded twice, once at the time of the safety 
analysis, and then at the end of my tenure as we had run out funds and time. The first 
time it was done at the request of the risk-reviewer. It was important to do so as 
hypotension in this group of patients with significant cardiovascular disease could 
have significant consequences. It could be suggested that somebody other than the 
main trial co-ordinater should do this, but this would involve extra personnel who were 
not available. In my defence however it is important to note that that the Duplex 
sonographer always remained blinded and hence the PSVR and ABPI measurements 
were done in an unblinded manner.
At the end my appointment as the coordinator we had run out of funds to continue the 
trial and recruit more patients. Hence it was decided to break the code and analyse the 
data we already had. It is impossible to get more funding without the interim results. 
The implications of this on the statistics is that in order to achieve the same power i.e. 
80% we would now have to get more numbers that originally estimated. After
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consulting with a statistician the best way to counteract the greater chance involved in 
a significant result, would be to increase the level of significance needed to p<0.025 
which necessitates an increase in the numbers needed in each group by 10%.
Having said all of the above there are I feel a few lesions we can learn from the trial 
data. The trial confirmed that the treatment is indeed feasible and practical in a clinical 
setting. Although there would still be a lot of different people involved in providing 
the treatment experience from application of PDT in other fields such as esophageal 
and oral cancers suggests this. The absence of any blinding and randomisation process 
and application of the PDT as standard treatment makes this easier.
I have shown that ALA can cause hypotension in patients with significant 
cardiovascular morbidity. Although the mechanism of this is not completely clear it 
appears to respond consistently to simple remedies. The hypotension is seen in patients 
with pre-existing cardiovascular disease. This has been reported before in elderly 
patients who received ALA-PDT for bladder cancer.214 In our study vasodilators and 
diuretics appeared to potentiate the hypotensive effects of ALA-PDT. This has not 
been previously reported. Although all patients in the study whether receiving 
treatment or placebo showed some drop in BP, the drop was significantly more in the 
ALA-PDT group. While the exact cause of this is not known, a previous studies using 
Swan-Ganz monitoring suggested that the hypotension is caused by peripheral
J I  c
vasodilatation and possibly a volume shift out of circulation. That study showed that
both systolic and diastolic pressures fell along with a fall in peripheral vascular 
resistance. However the pulmonary capillary wedge pressure remained
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normal in the same study. It is not clear whether it is ALA, PpIX or one of its 
metabolites which causes these effects. The timing of the hypotension suggests that it 
would be either the PpIX or another metabolite. Herman et al reported hypotension 2-4 
hours after oral administration of ALA. However hypotension in our series was 
slightly later at a mean of 5 hours after 1st fraction of ALA. (Figure 9.6) This may be 
partly because in their study ALA was administered in a single bolus dose of 60 mg/kg 
while in our study we administered it in three divided doses. It has previously been 
shown that blood levels of PPIX peak between 8-10 hours after administration. 
However, high levels of PPIX are seen from about 4 hours. This is consistent with the 
timing of the hypotension. No previous study has addressed the issue of how to 
prevent or treat this hypotension. Among the first 30 patients, those who developed 
hypotension responded immediately to the fluid infusion. All of them recovered their 
blood pressure within 30-60 minutes. Only one patient was symptomatic with the 
hypotension. This was a patient of known significant ischaemic heart disease who 
developed angina. This responded to GTN and the fluid infusion. All the other patients 
were asymptomatic. No patients suffered any lasting consequences from the 
hypotension. By 9 hours after oral intake the blood pressure in all the patients had 
returned to normal. Protocol changes were made as a result of this finding on the 
safety review. All patients were preloaded with a litre of crystalloid (normal saline) 
and their anti-hypertensives were omitted on the day of the treatment. Once the 
protocol changes were put into place none of the patients developed any significant fall 
in blood pressure, i.e. no systolic pressure <100 mm Hg. was recorded. None of the 
patients have had any cardiovascular symptoms. We recommend that all
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Time in hours
Figure 9.6 Bar Histogram showing time taken in hours for the blood pressure to 
fall to its lowest recording after ingestion of ALA. Most patients recorded maximum 
drop at 5-6 hours which corresponded with time for maximum concentration in the 
vessel wall. This drop was prevented by preloading patients with a litre o f crystalloid.
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patients with significant cardiovascular risk factors should have these measures put 
into place during ALA PDT.
Besides these effects no other significant complications were seen. Any pain, which 
was encountered with light delivery, can be prevented by prophylactic analgesics and 
reducing the light delivery rate to 80 mW/cm. The mild photosensitivity seen with 
some patients was self-limiting. In spite of taking all precautions to prevent exposure 
to direct sunlight some exposure could not be avoided in these patients as they did not 
necessarily stay in their bed during the 24 hours after ALA intake.
ALA had no effect on renal or liver function tests.
The laser source used in the pilot study was a copper vapour dye at 635 nm. For this 
study we used a diode laser at 635 nm. This is solid state and very consistent in its 
output. Being compact it is easy and safe to transport. The balloon used in the study 
was custom-made with a transparent core in order to allow the laser light to shine 
through. It was however very similar in all other respects to a standard balloon 
catheter. Since red light is absorbed by blood the lumen had to be occluded during 
light delivery. The balloon pressures were kept low during light delivery for 2 reasons. 
Firstly distension of the arterial wall might cause some hypoxia in the arterial wall 
compromising the PDT effect. Secondly keeping the balloon and the artery distended 
for 8 minutes might compromise the mechanical integrity of the vessel. It is important 
that an appropriate dose of Heparin is administered intra-arterially during the 
procedure in order to prevent thrombosis post procedure. Stasis of blood in the artery 
distal to the balloon will inevitably lead to thrombosis unless adequately
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heparinised. The 3 patients who did have post procedure thrombosis in the treatment 
group were not given adequate doses of the heparin which probably lead to the poor 
result.
When the follow-up results at 6 months are analysed it is difficult to draw any strong 
conclusions from it. The bottom line is that 18 patients in the treatment arm had a 
patent angioplasty site at 6 months compared to 15 in the control arm. If one analyses 
this in an intension to treat manner the primary patency is 55% in the treatment are and 
45 % in the control arm. However I do not feel this is a true reflection of the result and 
these results are better looked at as group who received full treatment or completed 
protocol. In the control arm this number is the same i.e. 28 but in the treatment arm 26 
received treatment, but 1 was lost to follow-up and hence only 25 completed protocol. 
Hence the primary patency in the treatment arm in all patients who received treatment 
is 69% and 53% in the control arm. Further in the treatment arm the primary patency 
in the patients who completed the protocol is 72%. Just to complicate these results 
further acute post-procedure thrombosis is a different problem from restenosis and 
hence should not be analysed as the same outcome. This is one of the main reasons 
this data cannot be presented and analysed as an actuarial life table or Kaplan Meier 
analysis. (This is the view of the consultant statistician). Another reason this data 
cannot be analysed as a life-table analysis is that this assumes that once the event has 
taken place it cannot reverse back. However in my data there are patients who have 
restenosis demonstrated on PSVR at 3 months or immediate post-procedure who have 
patent vessels at 6 months. The only conclusion one can draw from this data is that the
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application of PDT as an adjuvant to PTA is possible in the clinical setting and there is 
a trend for reduced restenosis in the treatment group. This is not statistically significant 
and should be interpreted accordingly.
One has to look at these results compared to the other approaches in vogue for 
treatment and prevention of restenosis. Brachytherapy and drug eluting stents are 2 
methods currently in use.
There have been a number of trials showing the efficacy of brachytherapy in the 
coronary circulation.216'224 Brachytherapy is licensed for use in treatment of in-stent 
stenosis. Radiation can be sourced either from p emitting sources such as yttrium or 
phosphorous beads or y irradiation from iridium 192 wires. It however has not 
completely eliminated restenosis and rates between 15 and 58% have been recorded at 
6 months. This compares very well to our study. Its usefulness in the femoro-popliteal 
artery has recently been shown in a randomised controlled trial comparing PTA with 
brachytherapy with PTA alone. Patency at 6 months and one year were significantly 
better in the former.218 Since the work on my trial was completed, Brachytherapy has 
been withdrawn as licenced treatment for restenosis because of the efficacy of DES.
The most common complications seen with brachytherapy are edge stenosis, late 
thrombosis and aneurysm formation. This is due to lack of re-endothelialisation and a 
prolonged inflammatory response. This has necessitated the use of long term 
anticoagulation. All of these problems are potentially avoidable with adjuvant PDT. 
Animal studies have confirmed re-endothelialisation within a few days of treatment
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and no late problems were recorded either in the pilot study or in our study.
Since this trial was suspended Drug eluting stents (DES) have all but revolutionised 
the prevention and treatment of restenosis. In 2002 when I finished my study the DES 
was just being trialled. Published results now suggest a restenosis rate of between 5- 
9% at 1-2 years, effectively reducing restenosis compared to stent only patients by 60- 
90%.225'228 The stents are coated with agents such as sirolimus and paclitaxel both of 
which are anti-proliferative agents which prevent restenosis by inhibiting VSMC 
proliferation. A recent study has also documented its use in the treatment of in-stent 
restenosis. DES are now licensed for use for de-novo angioplasty and it is anticipated 
that they will be used for restenosis as well. There are still a few words of caution with 
drug-eluting stents. High concentration gradients of the drug at the stented site could 
lead to lack of vessel healing especially re-endothelialisation and thinning of the vessel 
wall. As with brachytherapy this could lead to late thrombosis, stent displacement and 
aneurysm formation. It is currently recommended that patients stay on anticoagulation 
(fractionated heparin or warfarin) for up to 6 months after brachytherapy which 
obviously adds to both the morbidity and cost of treatment. It is as yet unclear as to 
how much anti-platelet treatment is needed for patients with drug eluting stents. 
Current recommendation are 6-12 months. As far as PDT is concerned, the lack of any 
thrombotic complications and good evidence to show endothelial re-growth fairly 
quickly after the procedure indicates no need for anticoagulation. Finally there is the 
question of cost. With out doubt all of these treatments are expensive. The cost of 
every treatment of brachytherapy has been put at over $3000 and that of Sirolimis
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stents is approximately $2500. While at present the PDT treatment was subsidised it is 
estimated that each dose of ALA would be about £500 while the extra equipment 
needed would also add to the cost. These have to be balanced out against the savings 
made by the reduced need of re-intervention and the reduced need of surgery.
This study shows that PTA with adjuvant PDT is clinically feasible and safe with 
simple precautions. The study also highlights the problems associated with running a 
randomised controlled trial. The smooth running of a RCT requires a concerted and 
meticulous approach to sticking to the protocol of the trial and considerable 
cooperation from all the personnel involved. Although the study has not been 
completed my results show a trend toward benefit in reducing restenosis when ALA- 
PDT is used in conjunction with PTA. We eagerly await the final results of the study.
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Patient
No. Sex Age
PSVR ABPI
pre post 3 mot 6 mot pre post 3 mot 6 mot
1 F 63 2.65 2 2.67 2 0.55 0.54 0.53 0.73
10 F 78 1.7 0.65 0.9 0.9 0.8 0.83 0.94
11 F 73 1.6 1.3 1.5 1.8 0.7 1 0.94 0.94
12 F 55 2.2 1 1 1 0.7 1 1
14 M 78 4 0.96 1.26 1.3 0.8 0.9 1
15 M 78 0 1.2 1.3 1.4 0.89 1 0.93 1
19 M 80 3 1 0.91 0.7 0.73 0.95 0.9 1
22 M 72 4.6 1.63 1.85 1.84 0.9 0.9
24 M 75 4 1.2 1.6 1.8 0.67 0.88 0.74
27 M 67 2.96 1.5 1.29 1.54 0.76 1 1 1
30 M 78 0 1.33 1.28 1.29
31 M 58 4.03 1.6 1.54 0.3 0.94 0.88
33 F 70 2.7 1.6 1.42 1.21 0.58 0.84 0.87 1
39 F 81 3 0 0 0 0.83
40 F 73 2.22 2.13 1.97 1.79 0.79 0.86 0.96 1
44 M 48 2.57 1.74 3.29 2.26 0.7 0.7 0.69 0.9
47 M 79 2.06 1.7 1.35 1.15 0.8 0.71 0.89 0.64
48 M 60 0 0 0 0 0.5 0.44 0.57 0.63
52 M 52 0 0 0 0 0.65 0.64 0.71 0.76
53 F 88 1.77 0.8 2.14 3.16 0.46 0.71 0.63 0.61
57 M 60 1.87 1.02 1.26 3.43 0.87 0.87 0.9 0.92
59 M 72 3.27 2.68 1 0 0.23 0.44 0.67 0.6
60 F 73 1.85 2.48 1.85 1.93 1 0.89 0.9 0.77
61 F 73 0 1.7 1.7 1.64 0.58 1 1 1
62 M 68 0 2.5 1.77 2.25 0.6 1 1 1
Table 9.5 Follow-up PSVR and ABPI data in treatment group in RCT
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Patient
No. Sex Age
PSVR ABPI
pre post 3 mot 6 mot pre post 3 mot 6 mot
2 F 63 4.08 3.63 3.81 2.5 0.64 0.83 0.94 0.92
3 M 80 0 1.83 0.89 1.3
7 F 78 1.88 0.7 2.7 2.1 0.54 0.56 0.5 0.51
8 M 55 4 2.5 1.6 1.4 0.82 0.9 1 1
9 F 76 3.6 1.7 1.2 1.7 0.9 0.9 1 1
13 M 73 2.8 1 1.25 1 0.4 0.65 1 0.9
16 F 74 2.11 1.63 1.59 1.8 0.7 0.95 0.9 0.9
17 F 76 3 1.31 1.45 1.6 0.74 0.7 1 1
18 M 75 3 1.1 0.5 0.6 0.7 1 0.82 1
21 M 57 3.25 1.52 1.09 0.81 1 1 1 1
23 F 89 3.1 0.74 1.5 2.73 0.57 0.73
25 M 79 3.61 0.88 1.59 1.15 1 1 0.95 1
26 F 81 2.45 2.12 2.32 2.4
28 F 67 0 1.74 1.73 1.26 0.47 0.44 0.54 0.48
32 F 75 6 1 2.9 2.2 0.57 0.93 0.74 0.62
34 F 73 4.01 3.26 3.06 3.5 0.65 0.7 0.8 0.76
35 M 72 0 0 0 0 0.43 0.5 0.5 0.48
36 M 58 1.85 1.42 1.54 1.7
37 F 75 7.8 9.47 1.45 3.56 0.83 1.19 1 0.71
38 F 70 2.5 1.93 1.27 1.44 0.8 0.77 0.88 0.95
41 M 83 3.8 1.05 1.35 0.7 1 0.8
46 F 3.57 1.29 1.51 3.36 0.63 0.97 0.89 0.65
50 M 70 3.35 2 2.64 2.34 0.7 1 0.73 0.93
54 F 80 2.1 1.5 0 0 0.65 0.66 0.8 0.71
56 F 73 1.85 2.42 2.71 2.5 1.25 0.8 1 1
58 M 56 1.87 2.58 1.05 1.7 0.76 1 1 0.85
64 M 64 2.41 0.48 0.75 1.8 0.58 0.55 0.56 0.52
66 M 74 2.61 1.65 2.28 2.96
Table 9.6 Follow-up PSVR and ABPI data in control group in RCT
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Chapter 10. Conclusions and the future
Restenosis and NIH are brought about by a combination of complex biological 
mechanisms which interact in a manner which is not fully understood Review of 
current literature has led me to conclude that restenosis is a diverse process brought 
about by a combination of different pathophysiologies. The extent and mechanism of 
these changes are not fully understood and because of this a number of different 
biological and mechanical approaches have been used to combat this with varying 
success. At the time of writing drug-eluting stents seem to be the flavour of the month 
with very good medium term results.
Conclusions:
The main aims of this thesis were to optimise the use of PDT with stents and to 
conduct a randomised controlled study to establish its efficacy as an adjuvant to PTA. 
In summary I can draw the following conclusions from my thesis.
Animal studies:
1. Systemic ALA PDT is feasible as an adjuvant to stenting in the rabbit iliac models 
using appropriate sized versions of standard clinical equipment. This is the first study 
to demonstrate this.
2. The optimum effects are achieved by intravenous delivery of ALA 3 hours before 
the procedure, and light application before stent delivery.
3. When PDT is given before stent delivery there is almost complete loss of medial
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VSMC at 3 days. There is no significant loss when PDT is given after light delivery.
4. When PDT is given before stent delivery there is significant inhibition of in-stent 
restenosis at 28 days. This leads to a wider lumen in these vessels. As these vessels are 
stented there is no effect on remodelling. Changing the dosimetry may improve the 
results further.
Clinical study:
1. Long term follow-up has shown restenosis in only one patient at 4 years with only 
minimal symptoms and no limb loss. It is important to note that these were a group of 
patients who were at high risk of restenosis.
2. Our randomised study using PTA with adjuvant PDT suggests that the incidence of 
restenosis could be reduced by our technique. While this failed to reach statistical 
significance with the number of patients recruited there is a trend toward reducing 
restenosis and we are optimistic that on completion of the trial we will achieve results 
that will show statistical significance.
Future work:
However while answering a lot of questions these studies also raises new ones. While 
the rabbit iliac model is a suitable model for studies on restenosis the pig model 
mimics human anatomy and pathophysiology more closely. Both the iliac and 
coronary arteries in the pig are easily accessible and would provide an ideal model to 
test clinical techniques with almost the same equipment as for clinical use. It also
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provides a good model to test the applicability of the technique in the coronary 
circulation and consequently its effect on myocardium both intra and post procedure. 
This is especially important given light delivery times of 8-10 minutes. Once safety 
and efficacy is established in the pig model the next step will be to test it in a clinical 
pilot study followed if successful in a randomised controlled study. The other issue to 
be considered is the use of alternative photosensitisers which have faster concentration 
time, appropriate level of effects and less photosensitivity. This last factor is especially 
important in vascular surgery in case patients need emergency surgery because of 
complications of angioplasty and stenting.
Although the results of the randomised controlled trial are encouraging they are not 
conclusive. The trial is still ongoing although currently suspended due to lack of funds. 
It is hoped that on conclusion it will prove the efficacy of PDT as an adjuvant to PTA. 
However one has to consider the other techniques being used for preventing restenosis 
especially drug-eluting stents which have shown excellent results in the short to 
medium term. The results with DES are so good that the licence for use brachytherapy 
for in-stent restenosis has very recently been withdrawn. While it is highly likely the 
DES with the standard first line treatment for coronary occlusive disease its role in 
PVD has not yet been defined. PDT may have a particular role to play in the peripheral 
vessels where stenting has not produced good results. It may also play a role in failures 
of DES. It has the particular advantage of being safe to use repeatedly with no 
apparent adverse effects. While the use of PDT, drug-eluting stents and brachytherapy 
concurrently has not yet been tested, it may provide another direction of attack.
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As briefly mentioned in the previous chapter cost still remains an issue. None of the 
treatments currently under investigation or in use are cheap. But they are expensive 
precisely because they are in the developmental stage. Common clinical use will 
certainly bring the costs down because of mass production. This is paramount in 
widespread application of these techniques, although companies will have to recoup 
their research costs to make a profit. Certainly cheaper sources of light such as LEDs 
are currently being investigated and may prove useful.
In conclusion PDT is effective in preventing in-stent and angioplasty restenosis, but a 
lot more work needs to be done to establish its best role in everyday clinical use.
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Protocols
RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC
THERAPY TO REDUCE RESTENOSIS
Patient Patient Date of Visit:  I _____ I _
Number: ______  name: _____
Telephone no: Trial number
GP name and telephone no:
SCREENING VISIT -  MEDICAL HISTORY
Has the patient any significant medical history? 
Q Yes (Specify) □  No
Body System Description
General Body 
(allergy etc)
Cardiovascula
r
IHD
Hypertension
CVA/TIA
Arterial Surgery
OTHERS
Diabetes mellitus
Renal impairment
Has the patient had previous PTA?
□  Yes (Specify) NoD
Patient Patient Date of Visit:  I ____ /
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC 
THERAPY TO REDUCE RESTENOSIS 
Number: ______  Initials: _____ Trial number:
SCREENING VISIT -  PHYSICAL EXAMINATION
Sex: □  Male DFemale Date of Birth:______I  I______
Month Day Year
Weight: ________ kg Blood Pressure:  / _______ mm Hg Heart Rate: _
bpm
Smoking?D Yes ^No □  gx
Intermittent claudication? n  Yes □  No (If “Yes” distance before claudication = _  
meters)
Ischaemic rest pain? L] Yes L] No Tissue loss □  Yes □  No
Pulses:Right: Fern  Pop  DP ______  PT____
Left:__ Fern_____ Pop____  DP ______  PT__ _
□  PE NORMAL
ANATOMY DESCRIBE ABNORMALITY BELOW
Head, Ears, Eyes, 
Nose, Throat, Mouth
Neck
Chest
Heart
Abdomen
Extremities
Nervous System
Lymph Nodes
Skin & Appendages
Other (Specify)
LFTs (including AST,ALT):
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC
THERAPY TO REDUCE RESTENOSIS
Pre-anqioplastv assessment
Patient Initials: Patient Number:
Number:
Date of Visit:
Stenotic Segment:
Side: R/L Length:
Site:
Distance from Medial Femoral Condyle (cms):
Other lesions:
Same side: Other side:
Run Off:
Luminal Diameter (mm): Angle 1
(Transverse)
(Longitudinal)
Lesion 1 
Lesion 2
Adjacent artery- Proximal 
Distal
Velocities (m/s)- Proximal
Lesion
Distal
Ankle Brachial Pressure Index (ABPI) at rest:
Trial
Angle 2
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC
THERAPY TO REDUCE RESTENOSIS
Patient Patient Date of Visit:  I ____ I .
Number: ______  Initials:   Trial number:
PROCEDURE
Time from drink to PTA:
Lesion site: _________
Lesion length: _____
Lesion side: □  Right □  Left □  Both
Distance from medial femoral condyle:
Access:
Balloon size (diameter and length):
No. of balloon positions:
Angiographic result:
Complications at time of PTA? □  Yes (Specify) □  No
Nausea/vomiting after procedure ? Yes (Specify) No □
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC
THERAPY TO REDUCE RESTENOSIS
Patient Patient Date of Visit:  I ____ I _
Number: ______  Initials:   Trial number:
DAY 1 FOLLOW-UP
Arterial complication? □  Yes (Specify) □  No
Surgery (emergency/elective)? □  Yes (Specify) □  No
Repeat PTA? □  Yes (Specify) □  No
Pulses: Riaht: Fern Pop DP PT
Left: Fern Pod DP PT
Access site:
Stenotic Segment:
Side: R/L Length:
Site:
Distance from Medial Femoral Condyle (cms):
Other lesions:
Same side: Other side:
Run Off:
Luminal Diameter (mm): Angle 1 Angle 2
(Transverse) (Longitudinal)
Lesion 1 
Lesion 2
Adjacent artery- Proximal
Distal
Velocities (m/s)- Proximal
Lesion
Distal
Ankle Brachial Pressure lndex(ABPI) at rest:
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC
THERAPY TO REDUCE RESTENOSIS
Patient Patient Date of Visit:  I ____ I
Number:   Initials:   Trial number:
  MONTH 1 FOLLOW-UP___________
Arterial complication? □  Yes (Specify) □  No
Surgery (emergency/elective)? □  Yes (Specify) □  No
Repeat PTA? □  Yes (Specify) □  No
Pulses: Riaht: Fern Pod DP PT
Left: Fern Pod DP PT
Access site:
Stenotic Segment:
Side: R/L Length:
Site:
Distance from Medial Femoral Condyle (cms):
Other lesions:
Same side: Other side:
Run Off:
Luminal Diameter (mm): Angle 1 Angle 2
(Transverse) (Longitudinal)
Lesion 1 
Lesion 2
Adjacent artery- Proximal
Distal
Velocities (m/s)- Proximal
Lesion
Distal
Ankle Brachial Pressure Index(ABPI) at rest:
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC
THERAPY TO REDUCE RESTENOSIS
Patient Patient Date of Visit:  I ____ I
Number:   Initials:   Trial number:
_______   MONTH 3 FOLLOW-UP
Arterial complication? □  Yes (Specify) □  No
Surgery (emergency/elective)? □  Yes (Specify) □  No
Repeat PTA? □  Yes (Specify) □  No
Pulses: Right: Fern Pop DP PT
Left: Fern P o d DP PT
Access site:
Stenotic Segment:
Side: R/L Length:
Site:
Distance from Medial Femoral Condyle (cms):
Other lesions:
Same side: Other side:
Run Off:
Luminal Diameter (mm): Angle 1 Angle 2
(Transverse) (Longitudinal)
Lesion 1 
Lesion 2
Adjacent artery- Proximal
Distal
Velocities (m/s)- Proximal
Lesion
Distal
Ankle Brachial Pressure Index(ABPI) at rest:
Patient Patient Date of Visit: / I
RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC 
THERAPY TO REDUCE RESTENOSIS 
Number: ______  Initials:   Trial number:
MONTH 6 FOLLOW-UP 
Arterial complication? □  Yes (Specify) □  No
Surgery (emergency/elective)? □  Yes (Specify) □  No
Repeat PTA? □  Yes (Specify) □  No
Pulses: Right: Fern Pop DP PT
Left: Fern P o d DP PT
Access site:
Stenotic Segment:
Side: R/L Length:
Site:
Distance from Medial Femoral Condyle (cms):
Other lesions:
Same side: Other side:
Run Off:
Luminal Diameter (mm): Angle 1 Angle 2
(Transverse) (Longitudinal)
Lesion 1 
Lesion 2
Adjacent artery- Proximal
Distal
Velocities (m/s)- Proximal
Lesion
Dist
Ankle Brachial Pressure Index(ABPI) at rest:
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC THERAPY TO REDUCE RESTENOSIS
Patient Number:   Patient Initials:
CONCOMITANT MEDICATIONS
I I None
Generic Name
(Pleas* use brand name for combination drugs)
Unit Dose Route Frequency Indication Date Started ♦
Month Day Year
Date Stopped
Month Day Year
□  Unknown
/ /
G Continuing 
/ /
□  Unknown
/ /
G Continuing 
1 1
G Unknown
/ /
G Continuing 
/ /
□  Unknown
/ /
G Continuing 
/ /
G Unknown
/ /
G Continuing 
/ /
G Unknown
1 1
G Continuing 
/ /
G Unknown
1 1
D  Continuing 
/ /
G Unknown
/ /
G Continuing 
/ /
G Unknown
/ /
G Continuing 
/ /
G Unknown 
/ /
G  Continuing
1 1
G Unknown
/ /
G Continuing
/ /
G Unknown
/ /
G Continuing
/ /
Q  Unknown
n  1 1
G Continuing 
/ /
*—1 Unknown
/ /
G  Continuing 
/ /
G Unknown
/ /
G Continuing 
/ /
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC THERAPY TO
REDUCE RESTENOSIS
Patient Patient
Number: ______  Initials:
ADVERSE EXPERIENCES
Did the Patient report any new problem that was not present at the initial visit, or 
that has worsened since initial visit ?
n  Yes (Specify) D No
Adverse experience Date of onset Duration Severity Study Drug 
relationship
/ /
□  Continuing ___ Mild
___ Moderate
___ Severe
___ Unrelated
___ Related
Month Day Year Days Hrs Min.
/ /
q  Continuing ___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year Days Hrs Min.
/ /
□  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year
/ /
□  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year
/ /
D  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year
/ /
□  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year
/ /
□  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year
/ /
D  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
___ Related
Month Day Y ear
/ /
O  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year
/ /
□  Continuing
Days Hrs Min.
___ Mild
___ Moderate
Severe
___ Unrelated
Related
Month Day Year
Cutaneous photosensitivity? □  Yes (Specify) □  No
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RAAPT TRIAL
RANDOMISED ANGIOPLASTY AND ADJUVANT PHOTODYNAMIC THERAPY TO
REDUCE RESTENOSIS
Patient Patient
Number: Initials:
UNBLINDED LASER PHYSICIST WORKSHEET
Date: Physicist:
Laser used: Wavelength: nm
Fibre used:
Calibration factor:
Previous uses:
Dose of ALA: mg
Time of light delivery for PDT:
Time of first dose:
Power used:
Laser energy:
Diffuser diameter: 
Diffuser area:___
mW/ cm2 Duration: sec
J/cm2
mm
cm'
Number of applications:
Note area = 5.02 cm2 —► 251 J, 0.4 W
area = 6.28 cm2 — ► 314 J, 0.5 W
area = 7.54 cm2 —► 377 J, 0.6 W
area = 8.80 cm2 — ► 440 J, 0.7 W
4cm long, 4 mm balloon, 50 J/cm2, 
4cm long, 5 mm balloon, 50 J/cm2, 
4cm long, 6 mm balloon, 50 J/cm2, 
4cm long, 7 mm balloon, 50 J/cm2,
50 J at 80 mW implies 625 s (about 101/2 minutes)
DO NOT FORGET FRACTIONATION
1 minute when time counted down to 520 s.
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ROYAL FREE and UNIVERSITY COLLEGE LONDON
UNIVERSITY COLLEGE LONDON
National Medical Laser Centre
Charles Bell House 
67-73 Riding House Street 
London W1P 7PN
Researcher -  Mr Mahesh Pai Nurse n
Patient Name:
Hospital No:
Trial No:
Date:
CONFIDENTIAL 
PATIENT CONSENT
RANDOMISED CONTROLLED TRIAL OF ADJUVANT PHOTODYNAMIC 
THERAPY TO REDUCE RESTENOSIS AFTER PERCUTANEOUS 
TRANSLUMINAL ANGIOPLASTY TO THE SUPERFICIAL FEMORAL
ARTERY
M Pai, J Brooks, E Chaloner, M Adeseshiah C Bishop, J McEwan, S Bown.
Have you read the information sheet about this study? YES/NO
Have you had the opportunity to ask questions and discuss the study? YES/NO
MEDICAL SCHOOL ^  
S/IIW
UCL
HOSPITALS
Have you received satisfactory answers to your questions? YES/NO
Have you received enough information about the study? YES/NO
My questions have been answered by.................................................................................
I agree to take part in this study and I understand that I may withdraw at any time 
without giving a reason and without it affecting my subsequent care.
Signed  Print Name.
Witness  Print Name.
Investigator..............................................  Date.
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ROYAL FREE and UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL
UNIVERSITY COLLEGE LONDON / / |\ \
National Medical Laser Centre !
Charles Bell House lu J  JL,
67-73 Riding House Street 4 S S S S S S L
London W 1P7PN HOSPITALS
Researcher -  Mr Mahesh Pai 
PATIENT INFORMATION SHEET
RANDOMISED CONTROLED TRIAL OF ADJUVANT PHOTODYNAMIC 
THERAPY TO REDUCE RESTENOSIS AFTER PERCUTANEOUS 
TRANSLUMINAL ANGIOPLASTY TO THE SUPERFICIAL FEMORAL ARTERY
M Pai, J Brooks, E Chaloner, M Adeseshiah C Bishop, J McEwan, S Bown.
Symptoms arising from a blockage in the leg arteries may require an operation but can often 
be treated by a simpler procedure to stretch the artery open (angioplasty). Although 
angioplasty can be very effective in re-opening the blockage the problem can recur in up to 
one third of patients.
Photodynamic therapy (PDT) is a relatively new treatment that is already used in other 
branches of medicine and is associated with few side effects. Our preliminary studies show 
that PDT is also of value in preventing the leg arteries re-blocking after angioplasty.
In order to assess the technique thoroughly we need to compare standard angioplasty 
(control group) with standard angioplasty combined with PDT (treatment group). On 
enrolment into the study you would be randomly assigned to either the control or treatment 
group. Either way you would still receive angioplasty treatment.
The study would involve you taking a drink that may contain ALA (5-Aminolaevulinic 
Acid). ALA occurs naturally in the body, but by giving the body more we can make your 
arteries sensitive to laser light. During your angioplasty we may (if you were assigned to the 
treatment group) expose your artery to laser light to activate the ALA. Exposure to laser 
light should be painless.
The main side effect from ALA is skin sensitivity and so you would be kept in subdued light 
for 24hrs to prevent the possibility of sunburn. Sometimes the blood pressure falls during 
the hours after drinking the ALA. We know that increasing the fluid intake can avoid this. 
You will be given IV fluids in the period after drinking the ALA and will be encouraged to 
drink plenty of clear fluids. Moreover if you are on any tablets for hypertension or if you are 
on water tablets we will omit the last dose before you go down for your treatment.
After your angioplasty treatment you will be followed up by the research team one month, 
three months and six months later. This will involve an ultrasound scan (which is painless) 
of the artery that was treated.
You have absolutely no obligation to take part in this study and if you do take part then, of 
course, you can withdraw at any time without giving a reason and without it affecting your 
subsequent treatment.
If you do agree to take part then you will be asked to sign a consent form. The whole design 
of the study and the procedure will be explained to you.
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ROYAL FREE and UNIVERSITY COLLEGE LONDON MEDICAL SCHOOL
UNIVERSITY COLLEGE LONDON / / |\ \
National Medical Laser Centre
Charles Bell House 
67-73 Riding House Street 
London W1P 7PN
Researcher -  Mr Mahesh Pai 
Tel: 
All studies such as this are reviewed by an ethics committee at the hospital before they can 
proceed. This study was reviewed by the joint UCL/UCLH Committees on the Ethics of 
Human Research.
HOSPITALS
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